
A Competency-Based Guide to Curriculum Development





### TABLE OF CONTENTS

TABLE OF CONTENTS	2
INTRODUCTION	3
HOW TO USE THIS CURRICULUM OUTLINE	4
I. MEDICAL KNOWLEDGE	5
II. PATIENT CARE	17
III. PRACTICE-BASED LEARNING AND IMPROVEMENT	21
IV. SYSTEMS-BASED PRACTICE	22
V. INTERPERSONAL AND COMMUNICATION SKILLS	24
VI. PROFESSIONALISM	25
APPENDIX A. RHEUMATOLOGY MILESTONES 2.0	27
APPENDIX B. RHEUMATOLOGY ENTRUSTABLE PROFESSIONAL ACTIVITES	55
APPENDIX C. RHEUMATOLOGY CURRICULAR MILESTONES	
APPENDIX D. RHEUMATOLOGY TOOLBOX: ACTIVITIES AND ASSESSMENTS	

#### INTRODUCTION

The subspecialty of rheumatology includes a wide array of autoimmune, inflammatory, and non-inflammatory conditions that affect the musculoskeletal and other organ systems. The purpose of rheumatology training programs is to 1) train fellows to be accomplished practitioners and consultants in the rheumatic diseases, and 2) encourage the professional and scholarly attitudes and approaches of a competent subspecialist that are needed to maintain an understanding of current concepts in rheumatology as advances occur.

This Core Curriculum Outline updates the previous ACR Core Curriculum Outline for Program Directors (2006, 2015) and is designed to reflect the Next Accreditation System (NAS) and the importance of competency-based training and assessment in graduate medical education, as defined by the Accreditation Council for Graduate Medical Education (ACGME). Also included in this core curriculum outline are:

Rheumatology Milestones 2.0 (Appendix A) Rheumatology Entrustable Professional Activities (EPAs) (Appendix B) Rheumatology Curricular Milestones (Appendix C) Rheumatology Toolbox: Activities and Assessments (Appendix D)

The updated curriculum outline continues to be organized by the six ACGME core competencies. These are:

Medical Knowledge Patient Care Practice-based Learning and Improvement Systems-based Practice Interpersonal and Communications Skills Professionalism

The two major sections of Basic Science and Clinical Science are incorporated into the medical knowledge section, which was updated in December 2020. Clinical aspects of these areas reside in the patient care section. Those aspects of the Core Curriculum that pertain to practice-based learning and improvement, systems-based practice, interpersonal and communication skills and professionalism are expanded into their own individual major sections. The purpose of specifically highlighting the core competencies in the Core Curriculum Outline is to clarify their essential components. The description of how and where they are acquired in the course of fellowship training, projected trainee performance benchmarks, and suggestions for tools to measure that performance are delineated within the Rheumatology Curricular Milestones (Appendix C, 2015) and Rheumatology Toolbox (Appendix D), the latter containing the educational activities and evaluation tools employed during fellowship training.

A major update to this 2020 Curriculum Outline is inclusion of pediatric rheumatology within the outline rather than as an appendix and includes a minimum set of core knowledge in pediatric rheumatology for the adult trainee. The ACGME suggests that "programs with the qualified faculty and facilities provide training in pediatric rheumatic disease." The ACR recognizes that, because of the worldwide shortage of pediatric rheumatologists, many internist rheumatologists in clinical practice will be called upon to evaluate and treat children. The Core Curriculum reflects the ACR goal that every rheumatology fellow should have familiarity with pediatric rheumatic diseases, whether or not they have the opportunity to rotate through a pediatric rheumatology clinic. Because reading is not a substitute for direct experience, training programs are encouraged to find opportunities for their fellows to see patients in a pediatric rheumatology clinic. This outline is consistent with the requirements of the ACGME Review Committee for training in rheumatology and serves as a guide for Training Program Directors and fellows in meeting these requirements.

The Core Curriculum Outline presents a comprehensive view of the components of a competency-based training program in rheumatology and is meant to provide a detailed guide for Program Directors to use in developing their own fellowship training curriculum. Individual training programs are expected to adapt this outline for their own curriculum and may reflect their particular areas of expertise and resources. This document is meant to be a practical resource for Program Directors to provide detailed descriptions of general competencies in rheumatology and provide tools for performance markers and assessments in these areas (see Rheumatology Curricular Milestones and Rheumatology Toolbox, Appendix C and Appendix D, respectively).

#### HOW TO USE THIS CURRICULUM OUTLINE

This Curriculum Outline divides each competency into several sections. A <u>Definition</u> of the competency in the context of rheumatology training is provided. The <u>Essential Components</u> of each competency are then listed and described. These components can be used to provide the rationale for selected training activities. Documentation of a competency-based curriculum involves describing the specific educational activities through which the training program works to develop and assess the six ACGME core competencies in its trainees during the course of the fellowship training program. According to the ACGME Program Requirements for Graduate Medical Education in Rheumatology, while the description of each educational activity (e.g., rotation, conference, or research activity) should delineate its goals and objectives, fellow responsibilities by year of training, and level of fellow supervision, the structure and methods used to evaluate the development of competency and the means by which the Program Director documents the educational activity components of the curriculum are all at the discretion of the individual fellowship program and may vary widely from program to program. Several Appendices have been included to provide milestones and tools that can be used to develop and document a competency-based curriculum.

#### I. MEDICAL KNOWLEDGE

The subspecialty of rheumatology includes a wide array of autoimmune, inflammatory, and non-inflammatory conditions that affect the musculoskeletal and other organ systems. A working knowledge of the basic and clinical sciences that relate to musculoskeletal and rheumatic disease is fundamental to the practice of rheumatology. Recognition of normal and pathogenic processes of the immune system form the basis of reliable diagnosis and the development and use of an increasingly sophisticated range of immunomodulatory treatments for the rheumatic diseases.

Similarly, knowledge of the basis for and use of laboratory tests of immune activity is a principal asset of the practicing rheumatologist. Rheumatology trainees must also have practical understanding of the approaches and modalities used by other specialists and health professionals (Nurses, Nurse Practitioners, Physician Assistants, etc.) for the treatment of rheumatic diseases in order to manage the care of their patients effectively. Training programs must teach and emphasize the cognitive skills that are necessary to apply this detailed knowledge to problem solving for diagnosis, treatment and research of the rheumatic diseases.

#### **DEFINITION**

Medical knowledge refers to the assimilation of established and evolving biomedical, clinical, and cognate sciences, and to the application of this knowledge to patient care.

#### **ESSENTIAL COMPONENTS**

#### **BASIC SCIENCES**

- A. Anatomy and biology of musculoskeletal tissues: for each tissue, consider the embryology, development, biochemistry and metabolism, structure, function, and classification
  - 1. Connective tissue cells, including fibroblasts, chondrocytes, osteoblasts/osteocytes
  - Extracellular matrix (ECM) molecules: collagens (fibrillar collagens and minor collagens), proteoglycans/aggrecan, elastin, matrix glycoproteins. Enzymatic degradation of ECM (metalloproteases).
  - 3. Joints and joint tissues: diarthrodial joints, intervertebral discs, growth plate, synovium, cartilage (hyaline, elastic, and fibrocartilage), subchondral bone, meniscus.
  - 4. Bone: development, structure, turnover and remodeling (including the role of osteoclasts, osteoclasts, osteocytes, as well as hormonal and cytokine regulation)
  - 5. Muscle, tendons, ligaments.
  - 6. Vasculature and endothelium
  - 7. Skin
- B. Immunology
  - 1. Anatomy and cellular elements of the immune system
    - a. Lymphoid organs
      - i. Bone marrow, thymus, lymph nodes and tertiary lymph tissues
      - ii. Gross and microscopic anatomy, structure and function
    - b. Specific cells: for each cell type, the ontogeny, structure, phenotype, function, and major activation markers/receptors
      - i. Lymphocytes: T cells including naive, memory, and activated (Th1, Th2, Th17, regulatory): B cells: and innate lymphocytes
      - ii. Antigen presenting cells: dendritic cells, monocytes/macrophages
      - iii. Other cells: Neutrophils, eosinophils, natural killer
      - (NK) cells, mast cells, epithelial cells, endothelial cells, platelets, fibroblasts
  - 2. Immune and inflammatory mechanisms
    - a. Innate mechanisms
      - i. Acute phase reactants and enzymatic defenses

- ii. Complement pathways, activation, and regulation
- iii. Toll-like (TLR) and other pattern recognition receptors (PRR)
- iv. Inflammasome components, activation, and function
- v. Neutrophil extracellular traps (NETosis)
- vi. NK cell activation and regulation
- vii. Interactions with adaptive immune mechanisms
- b. Adaptive mechanisms
  - i. T cells: development, genetic basis of T cell receptor diversity, molecular basis of antigen recognition and cellular activation
  - ii. B cells: development, B cell receptor and antibody structure and genetic basis of diversity, cellular activation and effector functions Antigens: types, structure, processing, presentation, and elimination
  - iii. Major histocompatibility complex: structure, function, nomenclature, and immunogenetics
  - iv. Cellular activation and regulation: mechanisms of activation and suppression of function (e.g. T cell and B cell interactions via CD28:CD80/86)
- 3. Initiation of an immune response
  - a. Immune cell trafficking: adhesion molecules, chemokines
  - b. Inflammatory mediators: origin, structure, effect, site of action, metabolism, and regulation
  - c. Cytokines: origin, structure, effect, site of action, metabolism, regulation, signal transduction, and gene activation
- 4. Types of immune responses
  - a. Antibody-mediated: opsonization, complement fixation, and antibody dependent cellular cytotoxicity
  - b. Cell-mediated: cells and effector mechanisms in cellular cytotoxicity, granuloma formation, and delayed type hypersensitivity
  - c. IgE-mediated: acute and late-phase reactions
  - d. Mucosal immunity and the microbiome
  - e. Pathologic immune responses: immune complex-mediated (physicochemical properties and clearance of immune complexes), graft versus host response, abnormal apoptosis
- 5. Immunoregulation
  - a. Tolerance: mechanisms of central and peripheral tolerance, including clonal selection, deletion, and anergy
  - b. Cell-cell interactions: help and suppression; collaboration among cells for control of the immune response
  - c. Autoimmunity: pathogenesis of systemic and organ specific autoimmunity
  - d. Idiotype networks: inhibition and stimulation
- C. Crystalline disease metabolism
  - 1. Purine and uric acid metabolism
    - a. Purine: biochemistry, synthesis, and regulation
    - b. Uric acid: origin, elimination, and physicochemical properties
    - c. Purine pathway enzyme deficiencies and immunodeficiency: ADA, PNP
  - 2. Calcium-based crystal metabolism
    - a. Crystals: factors affecting formation, induction of inflammation
    - b. Genetic abnormalities contributing to crystal formation
- D. Genetics and epigenetics: monogenic vs. polygenic, single nucleotide polymorphisms, DNA methylation, histone modification
- E. Biomechanics of bones, joints, and muscles: principles of kinesiology of peripheral/axial joints and gait and how alterations in biomechanics contribute to musculoskeletal disorders
- F. Neurobiology of Pain
  - 1. Peripheral afferent nociceptive pathways (including joint innervation by nociceptors and proprioceptors).
  - 2. Central processing of nociceptive information (dorsal horn and supraspinal levels)
  - 3. Peripheral and central sensitization (hyperalgesia, allodynia, temporal summation)
  - 4. Acute vs. chronic pain.
  - 5. Biopsychosocial model of pain

#### **CLINICAL SCIENCES**

A. Rheumatic Diseases

For each disease, acquire knowledge of the epidemiology, genetics, disease pathogenesis, natural history, clinical expression (including clinical subtypes), pathology.

- 1. Rheumatoid arthritis
- 2. Spondyloarthritis
  - a. axial and peripheral: ankylosing spondylitis, reactive arthritis, psoriatic arthritis, inflammatory bowel disease-associated arthritis
  - b. arthritis associated with acne and other skin diseases like hidradenitis suppurativa, synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, and undifferentiated spondyloarthritis
  - c. non-radiographic axial spondyloarthritis
- 3. Lupus and antiphospholipid syndrome: drug-related; anti-phospholipid antibody syndrome primary and secondary
- 4. Scleroderma and other fibrosing skin disorders
  - a. Limited and Diffuse systemic sclerosis
  - b. Localized Scleroderma
  - c. Other fibrosing skin disorders (eosinophilic fasciitis, eosinophilia-myalgia syndrome, nephrogenic systemic fibrosis, scleromyxedema, scleredema of Buschke)
- 5. Other connective tissue diseases: Sjögren syndrome, mixed connective tissue disease, undifferentiated connective tissue disease, and overlap syndromes
- 6. Systemic vasculitides
  - a. Large vessel: giant cell arteritis/polymyalgia rheumatica, Takayasu arteritis
  - b. Medium vessel: polyarteritis nodosa, Kawasaki disease
  - c. Small vessel: ANCA-associated vasculitis such as granulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis), eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) and microscopic polyangiitis, anti-glomerular basement membrane disease, cryoglobulinemia, Immunoglobulin A vasculitis (formerly Henoch-Schönlein purpura)
  - d. Other vasculitis syndromes: hypocomplementemic urticarial vasculitis, Behçet disease, Cogan syndrome, cutaneous leukocytoclastic angiitis, primary central nervous system vasculitis
  - e. Miscellaneous: isolated aortitis, vasculitis from systemic disorders, infections, drugs, malignancies
- 7. Crystalline arthropathies: monosodium urate monohydrate (gout), calcium pyrophosphate dihydrate deposition disease, basic calcium phosphate (hydroxyapatite), calcium oxalate
- 8. Immune-mediated inflammatory myositis:
  - a. polymyositis including immune- mediated necrotizing myositis, dermatomyositis, antisynthetase syndrome, inclusion body myositis, myositis associated with other connective tissue diseases
  - b. Other myositis: ocular/orbital myositis, focal/nodular myositis, eosinophilic myositis, granulomatous myositis
- 9. Other autoimmune disease: relapsing polychondritis, panniculitis (lobular or septal [erythema nodosum]), adult-onset Still's disease, IgG4-related disease, retroperitoneal fibrosis, primary Raynaud's disease, neuromyelitis optica, interstitial pneumonia with autoimmune features (IPAF), sarcoidosis, Susac syndrome, palindromic rheumatism, autoimmune disorders associated with checkpoint inhibitors, orbital inflammatory disease, remitting seronegative symmetrical synovitis with pitting edema (RS3PE)
- 10. Autoinflammatory syndromes. See section B.1.h and B.1.i for complete list.
- 11. Inherited muscle diseases
  - a. Metabolic myopathies: glycogen storage diseases, lipid metabolism disorders, mitochondrial myopathies
  - b. Muscular dystrophies
  - c. Muscle channelopathies

- 12. Infectious
  - a. Infectious arthritides: bacterial (non-gonococcal and gonococcal), mycobacterial, spirochetal (syphilis, Lyme), viral (HIV, hepatitis B, hepatitis C, parvovirus, chikungunya, dengue), fungal, parasitic, Whipple disease
  - b. Post-infectious: acute rheumatic fever, arthritis associated with subacute bacterial endocarditis, intestinal bypass arthritis, post-dysenteric arthritides, post-immunization arthritis, other colitis-associated arthropathies
- 13. Metabolic, endocrine, and hematologic disease associated rheumatic disorders
  - a. Endocrine-associated diseases: rheumatic syndromes associated with diabetes mellitus, acromegaly, parathyroid disease, thyroid disease, Cushing disease
  - b. Hematologic-associated diseases: rheumatic syndromes associated with hemophilia, hemoglobinopathies, angioimmunoblastic lymphadenopathy or lymphoma, multiple myeloma, hemophagocytic lymphohistiocytosis/macrophage activation syndrome
- 14. Bone and cartilage disorders
  - a. Osteoarthritis: primary and secondary osteoarthritis
  - b. metabolic bone disease: low bone mass, osteoporosis, osteomalacia, bone disease related to renal disease
  - c. Paget disease of bone
  - d. Avascular necrosis of bone: idiopathic, secondary causes, osteochondritis dissecans
  - e. Others: transient osteoporosis, hypertrophic osteoarthropathy, diffuse idiopathic skeletal hyperostosis
- 15. Hereditary, congenital, and inborn errors of metabolism associated with rheumatic syndromes
  - a. Disorders of connective tissue: Marfan syndrome, osteogenesis imperfecta, Ehlers-Danlos syndrome, pseudoxanthoma elasticum, hypermobility syndrome
  - b. Mucopolysaccharidoses
  - c. Osteochondrodysplasias: multiple epiphyseal dysplasia, spondyloepiphyseal dysplasia
  - d. Inborn errors of metabolism affecting connective tissue: homocystinuria, ochronosis
  - e. Storage disorders: Gaucher disease, Fabry disease
  - f. Immunodeficiency: IgA deficiency, complement component deficiency, SCID and ADA deficiency, PNP deficiency, others
  - g. Others: hemochromatosis, hyperlipidemic arthropathy, myositis ossificans progressiva, Wilson disease, others
- 16. Non-articular and regional musculoskeletal disorders
  - a. Fibromyalgia
  - b. Myofascial pain syndromes
  - c. Axial syndromes: low back pain, spinal stenosis, intervertebral disc disease and radiculopathies, cervical pain syndromes, coccydynia, osteitis condensans ilii, osteitis pubis, spondylolisthesis/spondylolysis, discitis
  - d. Regional musculoskeletal disorders: in addition to bursitis, tendinitis, or enthesitis occurring around each joint, other characteristic disorders occurring at each specific joint site (e.g., shoulder: rotator cuff tear, subacromial bursitis, adhesive capsulitis, impingement syndrome; wrist: ganglion cysts, De Quervain tenosynovitis; trigger fingers/stenosing tenosynovitis, Dupuytren contractures; knee-synovial plica syndrome, internal derangements, popliteal cyst; foot/ankle: plantar fasciitis, achilles tendinitis, Morton neuroma; other: temporomandibular joint syndromes, femoral acetabular impingement, costochondritis)
  - e. Biomechanical/anatomic abnormalities associated with regional pain syndromes: scoliosis and kyphosis, genu valgum, genu varum, leg length discrepancy, foot deformities
  - f. Overuse rheumatic syndromes: occupational, sports, recreational, performing artists
  - g. Sports medicine: injuries, strains, sprains, nutrition, medication issues
  - h. Entrapment neuropathies: thoracic outlet syndrome, upper extremity entrapments, lower extremity entrapments
  - i. Other: peripheral neuropathies (polyneuropathy, small fiber neuropathy), mononeuritis multiplex, complex regional pain syndrome (formerly reflex sympathetic dystrophy), erythromelalgia
- 17. Neoplasms and tumor-like lesions

- a. Benign
  - i. Joints: loose bodies, fatty and vascular lesions, synovial osteochondromatosis, pigmented villonodular synovitis, ganglions
  - ii. Tendon sheaths: fibroma, giant cell tumor, nodular tenosynovitis
  - iii. Bone: osteoid osteoma
- b. Malignant
  - i. Primary: synovial sarcoma, osteosarcoma, chondrosarcoma
  - ii. Secondary: leukemia, myeloma, metastatic malignant tumors
  - Malignancy-associated rheumatic syndromes: carcinomatous polyarthritis, palmoplantar fasciitis, Sweet syndrome, paraneoplastic presentations of rheumatic diseases
- 18. Rheumatic diseases in special populations
  - a. Geriatric population
  - b. Pregnant women
  - c. Dialysis patients
  - d. Transplant patients
- 19. Miscellaneous rheumatic disorders
  - a. Amyloidosis: primary, secondary, hereditary
    - b. Charcot joint
    - c. Multicentric reticulohistiocytosis
    - d. Arthritic and rheumatic syndromes associated with plant thorn synovitis, scurvy, pancreatic disease, primary biliary cirrhosis, drugs, frost bite, and environmental agents
- B. Pediatric rheumatic diseases

Some rheumatic diseases in children and adults can share similar features of pathogenesis, presentation, clinical course, and treatment. These diseases (such as systemic lupus, scleroderma spectrum diseases, the systemic vasculitides, and enteropathic arthritides) are not specifically addressed in this section. Other diseases or specific aspects thereof that are unique or more prevalent in children are included in this outline of knowledge content.

- 1. Rheumatic diseases that occur primarily in children: diagnosis and recognition of similarities and differences to comparable diseases in adults
  - a. Juvenile idiopathic arthritis (JIA)
    - i. Special considerations in pediatric arthritis
    - ii. Exam variations to match developmental status
    - iii. Variable clinical presentations: painless effusions or contractures
    - iv. Variable rates of serologic markers by JIA subtype
    - v. Inflammatory markers may be normal even with active inflammation
  - b. JIA subtypes
    - i. Systemic Onset (Still's disease in adults) (also see autoinflammatory disease below)
    - ii. Oligoarticular
    - Polyarticular (RF positive, RF negative) (polyJIA, RF positive similar to adult RA)
    - iv. Enthesitis-related
    - v. Psoriatic arthritis
    - vi. Undifferentiated arthritis
  - c. Juvenile dermatomyositis
  - d. Kawasaki Disease
  - e. IgA Vasculitis (formerly known as Henoch-Schönlein Purpura, HSP)
  - f. Acute rheumatic fever and post-streptococcal reactive arthritis
  - g. Neonatal lupus syndrome
  - h. Monogenic autoinflammatory diseases:

- Inflammasomopathies: Familial Mediterranean Fever (FMF), hyperimmunoglobulinemia D syndrome (HIDS), tumor necrosis factor receptorassociated periodic syndromes (TRAPS), pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome (PAPA), and cryopyrin associated periodic syndrome (CAPS) including Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and neonatal-onset multisystemic inflammatory disease (NOMID)
- ii. Interferonopathies: STING-associated vasculopathy with onset in infancy (SAVI), Aicardi-Goutieres Syndrome, chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome, and coatomer protein complex subunit alpha (COPA) syndrome
- Others: deficiency of interleukin-1 receptor agonist (DIRA), deficiency of interleukin-36 receptor antagonist (DITRA), Majeed syndrome, Blau syndrome (NOD2/CARD15), A20 haploinsufficiency (HA20), deficiency of adenosine deaminase 2 (DADA2)
- i. Polygenic autoinflammatory diseases: Periodic fever with aphthous stomatitis, pharyngitis, and adenitis (PFAPA), chronic recurrent multifocal osteomyelitis (CRMO), and Schnitzler syndrome
- 2. Notable differences, major sequelae and life-threatening complications of rheumatic diseases that are seen in children
  - a. Systemic onset JIA

i.

- i. Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (MAS)
- ii. Cardiac tamponade
- iii. Lung disease (pulmonary arterial hypertension, alveolar proteinosis, interstitial lung disease)
- b. ANA+ oligo, polyarticular, and psoriatic JIA
  - Chronic uveitis
- c. Enthesitis-related arthritis
  - i. Some advance to ankylosing spondylitis
  - ii. May be HLA b27 associated
- d. Juvenile dermatomyositis
  - i. Rarely associated with malignancy
  - ii. GI vasculitis
  - iii. Calcinosis
  - iv. Joint contractures
  - v. Dysphagia and aspiration
  - vi. Interstitial lung disease
- e. Kawasaki Disease
  - i. Aneurysms of coronary and other arteries
  - ii. Hemophagocytic lymphohistiocytosis/Macrophage activation syndrome (MAS)
- f. IgA Vasculitis (formerly known as Henoch-Schonlein Purpura, HSP)
  - i. GI- intussusception, intestinal infarction
  - ii. Renal chronic IgA mediated glomerulonephritis
- g. Neonatal lupus syndrome
  - i. Congenital heart block
  - ii. Thrombocytopenia
  - iii. Hepatitis
- 3. Appropriate treatments of the above childhood rheumatic disorders and complications of

treatment

- 4. Non-rheumatic disorders in children that can mimic rheumatic diseases
  - a. Infectious or post-infectious syndromes
    - i. Septic arthritis and osteomyelitis
    - ii. Transient (toxic) synovitis of the hip
    - iii. Post-infectious arthritis and arthralgia including gastrointestinal and GU infections
    - iv. Post-viral myositis
  - b. GI-related autoimmune disorders
    - i. Autoinflammatory bowel disease
    - ii. Celiac disease
  - c. Orthopedic conditions
    - i. Legg-Calve-Perthes disease and other avascular necrosis syndromes
    - ii. Slipped capital femoral epiphysis
    - iii. Spondylolysis and spondylolisthesis
    - iv. Patellofemoral syndrome
  - d. Non-rheumatic pain
    - i. Benign limb pains of childhood ("growing pains")
    - ii. Benign hypermobility syndrome
  - e. Neoplasms
    - i. Leukemia
    - ii. Lymphoma
    - iii. Primary bone tumors (especially osteosarcoma and Ewing sarcoma)
    - iv. Tumors metastatic to bone (especially neuroblastoma)
  - f. Bone and cartilage dysplasias, and inherited disorders of metabolism (Marfan syndrome, osteogenesis imperfecta, Ehlers-Danlos syndrome, pseudoxanthoma elasticum)
- 5. Non-articular and regional musculoskeletal disorders
  - a. Pain amplification syndromes
    - i. Pediatric Fibromyalgia
    - ii. Complex Regional Pain Syndrome (CRPS) type I (also known as Reflex sympathetic dystrophy)
- 6. Special considerations in childhood of rheumatic diseases and treatments
  - a. Disease effects on growth
    - i. Accelerated or decelerated growth of limbs or digits affected by arthritis (muscle atrophy, leg length discrepancy)
    - ii. Altered growth of mandible in TMJ arthritis
    - iii. Short stature and failure to thrive
  - b. Regular surveillance for uveitis in JIA
    - i. Asymptomatic nature of most JIA-associated uveitis
    - ii. Screening schedule based on age of JIA onset, JIA type, duration of disease, ANA status
    - iii. Potential sequelae: Cataracts, glaucoma, synechiae, vision loss
- 7. Drugs
  - a. FDA approved drugs for childhood rheumatic diseases
  - b. Pediatric dosing and special considerations in terms of pharmacokinetics and drug metabolism

- c. Off label use of medications may be necessary
- 8. Child-specific side effects of chronic glucocorticoid treatment
  - a. Growth retardation
  - b. Delay of puberty
- 9. Physical and occupational therapy
  - a. Exercises
  - b. Splinting
- 10. Psychosocial and developmental issues
  - a. Peer and sibling interaction
  - b. Family adjustment
  - c. School accommodations for disability
  - d. School and recreational activities
  - e. Delayed or regressed developmental milestones
- 11. Transition to adulthood
  - a. Transition of care
- C. Therapeutic modalities and strategies
  - 1. Pharmacology: for each medication, the dosing, pharmacokinetics, metabolism, mechanisms of action, side effects, drug interactions, adherence issues, costs, and use in specific patient populations, such as chronic kidney disease and including fertile, lactating, and pregnant women and fertile men as well as across the age spectrum
    - a. Nonsteroidal anti-inflammatory drugs
    - b. Glucocorticoids: topical, intra-articular, systemic
    - c. Systemic anti-rheumatic drugs
      - i. DMARDs
        - (1) Anti-malarials
        - (2) Anti-inflammatory
        - (3) Anti-metabolites
        - (4) Alkylating agent
      - ii. Calcineurin inhibitors
      - iii. Biologic agents and biosimilar agents
        - (1) Interleukin inhibitors (1, 5, 6, 12, 17, 23)
        - (2) Tumor necrosis factor inhibitors (soluble or monoclonal)
        - (3) T cell co-stimulatory inhibitors
        - (4) B cell depletion therapy
        - (5) Inhibitor of B-lymphocyte stimulator
      - iv. Small molecule inhibitors of Janus kinase (JAK) enzymes
      - v. Phosphodiesterase 4 inhibitors
      - vi. Inhibitors of complement components
      - vii. Historical agents such as gold compounds, penicillamine, and minocycline
    - d. Urate lowering therapy
      - i. Xanthine oxidase inhibitors
      - ii. Uricosuric
      - iii. Uricase agents
    - e. Bone disorder medications
      - i. Bisphosphonates
      - ii. Anabolic agents
      - iii. RANKL inhibition

- iv. Sclerostin monoclonal antibody
- v. Hormonal therapy
- vi. Calcium and Vitamin D
- f. Vasodilators
  - i. Calcium channel blockers
  - ii. Topical nitrates
  - iii. Prostacyclin analogs
  - iv. Endothelin receptor antagonists
  - v. Phosphodiesterase 5 inhibitors
  - vi. Guanylate cyclase agonist
- g. Antibiotic therapy for septic joints
- h. Opioid and non-opioid analgesics
- i. Colchicine
- j. Agents used for pain modulation: anti-depressants, anti-convulsants, gapentinoids, muscle relaxants
- k. Cholinergics and non-pharmacologic agents used for the treatment of sicca symptoms
- I. Vaccines
- m. Intravenous immunoglobulin (IVIG)
- n. Plasma exchange
- o. Rehabilitation and disability Multidisciplinary approaches to rehabilitation and pain control: appropriate use of and referral/prescription to rehabilitation specialists and pain clinics
- p. Methods of rehabilitation: for each method, principles, mechanism of action, indications, precautions and contraindications, potential side effects, and costs
  - i. Exercise
  - ii. Rest and splinting
  - iii. Thermal Modalities
    - (1) Ultrasound
    - (2) Phonophoresis
    - (3) Spa therapy
    - (4) Icing
- q. Adaptive equipment and assistive devices
- r. Footwear and orthotics
- 2. Surgical and perioperative management
  - a. For each procedure, the fellow should demonstrate a working knowledge of indications, preoperative evaluation and medication adjustments, contraindications, complications, postoperative management, and expected outcome.
    - i. Bone biopsy
    - ii. Arthroscopy
    - iii. Synovectomy of tendons and joints
    - iv. Entrapment neuropathy release
    - v. Osteotomies: hip, knee
    - vi. Arthrodesis
    - vii. Spine surgery: radiculopathy, stenosis, and instability
    - viii. Reconstructive surgery of hand and foot
    - ix. Total joint replacement
    - x. Specific surgical management problems:
      - (1) Patient with rheumatoid arthritis
      - (2) Infected joint: arthroscopy vs. arthrotomy

- (3) Infected prosthetic joint
- (4) Patient with ankylosing spondylitis
- (5) Pediatric patient with rheumatic disease
- (6) Prevention and treatment of deep venous thrombosis
- (7) Peri-operative anti-rheumatic medication management
- 3. Complementary and alternative medical practices, including but not limited to: diet, nutritional supplements, acupuncture, chiropractic

#### **DIAGNOSTIC TESTING**

- A. Laboratory tests: rationale, methods for performing, and utility/limitations of specific laboratory tests including but limited to:
  - 1. Erythrocyte sedimentation rate, C-reactive protein, and other acute phase reactants (*ferritin, haptoglobin, ceruloplasmin, complement*)
  - 2. Rheumatoid factors, cryoglobulins, and circulating immune complexes (C1q)
  - 3. Anti-cyclic citrullinated peptide antibodies
  - Antibodies against nuclear antigens: ANA, anti-dsDNA, anti-Smith, anti-SSA, anti-SSB, anti-U1 RNP, anti-centromere, anti-histone, anti-ribosomal P, anti-topoisomerase 1, anti-U3 RNP, anti-RNA Polymerase III
  - 5. Lupus Erythematosus (LE) cell preparation
  - Myositis-specific autoantibodies (anti-Jo-1 and other anti-synthetases, anti-Mi-2, anti-SRP, anti-HMG CoA reductase [200/100], anti-TIF1-gamma [p155/140], anti-MJ [NXP-2], anti-CADM-140 [MDA-5], anti-SAE) and myositis-associated (anti-Ro, anti-U1RNP, anti-Ku, anti-PM-ScI) antibodies
  - 7. Other disease-associated auto-antibodies: anti-mitochondrial, anti-smooth muscle, anti-neuronal
  - 8. Anti-neutrophil cytoplasmic antibodies (anti-proteinase 3, anti-myeloperoxidase)
  - 9. Anti-phospholipid antibodies including RPR, lupus anticoagulant, anti-cardiolipin, anti-beta-2glycoprotein I and antiphosphatidylserine
  - 10. Antibodies to formed blood elements including direct and indirect Coombs testing, anti-platelet antibodies, anti-granulocyte antibodies
  - 11. Assays for complement activity (CH50) and components of the complement cascade
  - 12. Serum immunoglobulin levels, serum protein electrophoresis and immunofixation electrophoresis
  - 13. HLA typing (B27, B51, B5801)
  - 14. ASO and other streptococcal antibody tests
  - 15. Appropriate testing for Lyme disease, HIV, Hepatitis B, Hepatitis C, parvovirus, N. gonorrhea, chikungunya and other infectious agents
  - 16. Appropriate screening for hepatitis B, hepatitis C, tuberculosis
  - 17. Serum and urine measurements for uric acid
  - 18. Iron studies including total iron binding capacity, ferritin
  - 19. Flow cytometry studies for analysis of lymphocyte subsets and function
  - 20. Specific genetic testing
- B. Diagnostic imaging techniques: basic underlying principles and technical considerations in the use of plain radiographs, computed tomography, magnetic resonance imaging, ultrasonography and radionuclide scanning of bones, joints, periarticular and vascular structures
- C. Synovial fluid analysis: cell count and differential, Gram stain and bacterial culture, crystal identification, viscosity, and other special stains/analyses (AFB, fungal culture)
- D. Laboratory test-performance characteristics: principles of sensitivity, specificity, predictive value, and likelihood ratios

#### RESEARCH PRINCIPLES

- A. Basic Science Research: Fellows should demonstrate a basic knowledge of the principles of basic science research and the process of scientific experimentation and hypothesis testing including:
  - 1. Generating an experimental question and hypothesis

- 2. Experimental design
  - a. Designation of experimental group
  - b. Designation and selection of appropriate control group
  - c. Replication of results to assure reliability and validity
- 3. Laboratory techniques commonly used in research related to rheumatologic diseases basic understanding of methods
  - a. Clinical: ELISA, RIA, nephelometry, protein electrophoresis, multiplex bead-based immunoassays
  - b. Cellular: cell lines, lymphocyte proliferation, flow cytometry, fluorescence activated cell sorting (FACS), confocal microscopy
  - c. Immunohistochemistry and immunofluorescence of tissues.
  - d. Molecular: Western blot analysis, polymerase chain reaction; gene sequencing; genomics techniques (GWAS, SNPs, microarray techniques), proteomics techniques
  - e. Hybridoma and monoclonal antibody production
  - f. Mouse models: transgenic, knock-out/knock-in, chimeras
- 4. Statistical methods and reporting
  - a. Statistical tests for analysis of variables
  - b. Statistical significance and sample size
- B. Clinical Research: Fellows should understand the principles of research involving patients in order to answer clinically relevant questions, recognizing the limitations and biases of different study designs
  - 1. Generating an experimental question and hypothesis
  - 2. Research study design distinguish the critical components of clinical studies
    - a. Clinical trial design
      - i. Phase I clinical trials
      - ii. Phase IIa and IIb clinical trials
      - iii. Phase III clinical trials
      - iv. Randomized, double-masked, placebo-controlled trial
      - v. Cross-over trial designs
      - vi. Randomized discontinuation trial
      - vii. Open-label extensions
    - b. Observational study designs
    - c. Other study design
      - i. Meta-analysis
        - ii. Systematic Review
  - 3. Inclusion and exclusion criteria
  - 4. Concept of equipoise and its impact on study design
  - 5. Statistical methods and reporting
    - a. Sensitivity and specificity calculations
    - b. Odds ratios, hazards ratio, relative risk, number needed to treat, number needed to harm
    - c. Statistical significance, sample size, and power calculations
    - d. Student t-test, Chi-squared test, logistic regression, 95% confidence intervals
- C. Epidemiological and health services research: Fellows should recognize how research focused on population level measures, or on implementation and delivery of interventions is carried out at the local and global level
  - 1. Epidemiology study design
    - a. Types: Retrospective, case series, case-control, cohort, cross-sectional
    - b. Analysis: incidence, prevalence, correlation, predictive variables
  - 2. Outcomes measures
    - a. Patient reported outcomes (e.g. SF36, WOMAC, global assessments)
    - b. Disease activity indices (e.g. DAS, RAPID3, CDAI, SLEDAI, BASDAI, PASI, BVAS and others)
    - c. Composite indices (e.g. BILAG, SRI, BICLA, ACR Composite)
  - 3. Quality improvement science

- a. Plan-Do-Study-Act (PDSA) cycle
- b. Team leadership skills
- 4. Comparative effectiveness research
- D. Research Ethics: Fellows should know and practice the guiding principles of ethical research with a focus on the core principles of beneficence and non-malfeasance
  - 1. Guiding principles
    - a. Nuremberg code
    - b. Declaration of Helsinki
    - c. Belmont Report
  - 2. Independent review
    - a. Institutional Review Boards (IRB)
    - b. Data safety monitoring boards
  - 3. Informed consent
  - 4. Right to withdraw
  - 5. Data management
    - a. Confidentiality
    - b. Documentation
  - 6. Data security
- E. Critical literature review
  - 1. Evidence based medicine principles
  - 2. Critical appraisal of the literature

#### **TELEHEALTH PRINCIPLES**

- A. Fellows should demonstrate a basic knowledge of the principles of telehealth including:
  - 1. Types of Telehealth Encounters, as Categorized by:
    - a. Timing
      - i. Synchronous
      - ii. Asynchronous
    - b. Personnel Involved
      - i. eConsult
      - ii. Direct patient-to-provider virtual visits
      - iii. Patient to provider via mediator, where the patient is onsite with an axillary provider who may perform physical exam maneuvers and/or assist the patient with working telemedicine equipment
    - c. Method
      - i. Telephone visit
      - ii. Video visit
      - iii. Medical record review
    - Equipment Used in Virtual Medicine
      - a. Videoconferencing equipment (i.e. telephone, camera, etc.)
      - b. HIPAA Compliant Videoconferencing platforms (i.e. Zoom, Doximity, etc.)
      - c. Telemedicine peripherals (i.e. remote stethoscopes, otoscopes, ultrasound, etc.)
    - 3. Legal Regulations

2.

- a. Local, state, and federal licensure laws for telehealth
- b. Components of patients' informed consent for virtual encounters
  - i. Risks including breech of patient privacy, potential short-comings of virtual encounters, etc.
  - ii. Benefits including improved access to care, convenience, etc.

#### **II. PATIENT CARE**

The ability to provide quality patient care is the ultimate goal of clinical training in rheumatology. The fellowship program must require its trainees to attain competence in patient care to the level expected for independent practice, as defined by the Rheumatology Entrustable Professional Activities (EPA's) (Appendix B). Programs must define the specific knowledge, skills, behaviors, and attitudes required, as well as provide educational experiences as needed in order for their trainees to demonstrate quality patient care.

#### DEFINITION

Patient Care that is compassionate, appropriate, and effective for the treatment of disease and the promotion of health.

#### **ESSENTIAL COMPONENTS**

The essence of being a rheumatologist is the ability to use information derived about a patient (history, physical examination, laboratory and imaging studies) along with medical knowledge to orderly synthesize a differential diagnosis, plan of further evaluation and comprehensive management for the patient being evaluated for rheumatic disease or rheumatic disease manifestations. The rheumatologist should provide consultation when requested, in support of the primary care relationship, for patients with rheumatic symptoms and signs and appropriately integrate recommendations from other health care providers into the evaluation and management plan.

This may broadly be categorized under four components:

#### **COMPONENT 1 - INFORMATION GATHERING**

The fellow should be able to:

- 1. Obtain an accurate and comprehensive but relevant clinical history, including review of all available records.
- 2. Perform a thorough and relevant review of systems, and assess functional status of patients with rheumatic disease symptoms.
- 3. Perform and interpret a comprehensive, accurate physical examination, using common and advanced techniques, where applicable.
- 4. Perform and interpret the examination of all axial and peripheral joints, peri-articular structures, peripheral nerves and muscles.
- 5. Identify extra-articular findings that are associated with specific rheumatic diseases.
- 6. Recognize the indications for and costs of ordering laboratory tests and procedures to establish a diagnosis of rheumatic disease
- 7. Recognize the indications for and costs of different therapies used in the management of rheumatic diseases.
- 8. Recognize the indications for and demonstrate competence in arthrocentesis, joint and soft tissue injections. The fellow should be able to distinguish the anatomy, precautions (including OSHA requirements) and potential sequelae of arthrocentesis and demonstrate competency in obtaining synovial fluid from diarthrodial joints, bursae and tenosynovial structures after obtaining informed consent from the patient or caregiver.
- 9. Perform synovial fluid analysis including the examination and interpretation of synovial fluid under conventional and polarized light microscopy from patients with a variety of rheumatic diseases.

- 10. Obtain and interpret appropriate tests, including laboratory tests, imaging studies, and other indicated testing to evaluate patients presenting with known or possible rheumatic disease:
  - a. Radiographs of normal and diseased joints, bones, peri-articular structures and prosthetic joints
  - b. Bone densitometry
  - c. Arthrography, ultrasonography, computed tomography, magnetic resonance imaging of joints, bones, peri-articular structures and muscle
  - d. Radionuclide scans of bones and joints
  - e. Arteriograms (conventional, CT and MR) for patients with suspected or confirmed vasculitis
  - f. Computed tomography of lungs and paranasal sinuses
  - g. Magnetic resonance imaging of the central nervous system (brain and spinal cord)
  - h. Electromyograms and nerve conduction studies
  - i. Biopsy specimens including histochemistry and immunofluorescence of tissues relevant to the diagnosis of rheumatic diseases: skin, synovium, muscle, nerve, bone, minor salivary gland, artery, kidney and lung
  - j. Specific laboratory tests : See Medical Knowledge, Clinical Sciences, Diagnostic Testing A (*vide supra*)
  - k. Arthroscopy
  - I. Schirmer's and tests of corneal integrity; parotid scans and salivary flow studies

#### **COMPONENT 2 - SYNTHESIS OF TREATMENT PLAN**

Informed medical decision-making based on current scientific information and clinical judgment that also accounts for patient preferences and circumstances.

The fellow should be able to:

- 1. Construct a differential diagnosis in patients presenting with signs and symptoms related to rheumatologic diseases and to outline further testing necessary to establish the correct diagnosis
- 2. Construct and implement an appropriate treatment plan for the care of a patient with a rheumatologic problem integrating the prescribing of medications (oral, injectable or infused), counseling and psychosocial aspects, rehabilitative medicine, and, when necessary, surgical or other consultation. The fellow should be able to explain the rationale as well as the risks and benefits for the treatment plan
- Formulate and implement a management plan for patients with rheumatic emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care
- 4. Recognize disease-related exacerbations and formulate and implement a management plan
- 5. Refer to, or consult with other health care providers for the co-management of patients with rheumatic disease
- 6. Identify opportunities for referral to clinical registries and trials

#### **COMPONENT 3 - IMPLEMENTATION OF TREATMENT**

A. Prescribing medications and rehabilitation The fellows should be able to:

Demonstrate a working knowledge of clinical pharmacology including the dosing, pharmacokinetics, metabolism, mechanisms of action, side effects, drug interactions, compliance issues, costs, and use in specific patient populations, such as chronic kidney disease and including fertile, lactating, and pregnant women and fertile men as well as across the age spectrum.

- 1. Nonsteroidal anti-inflammatory drugs and adequate gastroprotection
- 2. Glucocorticoids: topical, intra-articular, systemic
- 3. Systemic anti-rheumatic drugs
  - a. DMARDs, small molecules: anti-malarials, sulfasalazine, methotrexate, leflunomide, azathioprine, cyclophosphamide, mycophenolate mofetil, calcineurin inhibitors, JAK kinase inhibitors, phosphodiesterase inhibitors
  - b. Biologic agents: interleukin inhibitors (1, 6, 12, 17, 23), tumor necrosis factor inhibitors, T cell co-stimulatory inhibitors, anti-B cell therapy
  - c. Historical agents such as gold compounds
- 4. Urate lowering therapy:
  - a. Xanthine oxidase inhibitors: allopurinol, febuxostat
  - b. Uricosuric: probenecid
  - c. Uricase agents: pegylated uricase, rasburicase
- 5. Bone disorder medications
  - a. Bisphosphonates: alendronate, risedronate, ibandronate, zoledronic acid
  - b. Anabolic agents: teriparatide
  - c. RANKL inhibition: denosumab
  - d. Hormonal therapy: estrogen, selective estrogen receptor modulators, calcitonin
  - e. Calcium and Vitamin D
- 6. Vasodilators
  - a. Calcium channel blockers
  - b. Topical nitrates
  - c. Prostacyclin analogs
  - d. Endothelin receptor antagonists
  - e. Phosphodiesterase inhibitors
  - f. Guanylate cyclase agonist
- 7. Antibiotic therapy for septic joints
- 8. Opioid and non-opioid analgesics
- 9. Colchicine
- 10. Agents used for pain modulation: anti-depressants, anti-convulsants, pregabalin, muscle relaxants
- 11. Anti-cholinergics and non-pharmacologic agents used for the treatment of sicca symptoms
- 12. Vaccines
- 13. Intravenous immunoglobulin (IVIg)
- 14. Plasma exchange
- B. Pain assessment and pain management

The fellow should be able to utilize:

- 1. Methods of pain assessment including visual analog scale scores, pain questionnaires
- 2. Non-pharmacological modalities of pain management including exercise, cognitive behavioral therapy
- 3. Pharmacological therapy including:
  - a. Immunosuppressive and anti-inflammatory management of underlying rheumatic disorder.
  - b. Analgesic agents including acetaminophen, nonsteroidal anti-inflammatory agents and narcotic analgesics.
  - c. Antidepressants
- 4. Means to identify physical impairment; relate the impairment to the observed functional deficits; prescribe appropriate rehabilitation (physical therapy, occupational therapy) to achieve goals to improve the defined impairment.

C. Surgical management

The fellow should be able to:

- 1. Distinguish indications for surgical and orthopedic consultation in acute and chronic rheumatic diseases.
- 2. Perform peri-operative management of the surgical patient:
  - a. Peri-operative evaluation, appropriate referral and medication adjustments.
  - b. Rehabilitation of the patient with rheumatic disease after a surgical or orthopedic procedure, as well as aspects of post-operative medical management pertaining to the rheumatologic condition.
- D. Non-pharmacologic management
  - The fellow should be able to:
    - 1. Describe complementary and unconventional medical practices: diet, nutritional supplements, antimicrobials, acupuncture, topical therapeutic agents, homeopathic remedies, venoms, and others.
    - 2. Perform patient education and counseling
- E. Preventive medicine and proactive care

The fellow should be able to:

- 1. Appropriately assess and manage of bone health in a patient starting or taking glucocorticoid therapy
- 2. Counsel for risk factor modification for patients at risk for fracture
- 3. Recognize the importance of lipid panel monitoring in patients with rheumatic disease
- 4. Appropriately implement prophylaxis against pneumocystis pneumonia
- 5. Counsel for tobacco cessation
- 6. Appropriately screen for risk for reactivation of infectious diseases (viral hepatitis, tuberculosis) in patients beginning disease modifying, small molecules or biologic therapy
- 7. Counsel for appropriate dental evaluation and management
- 8. Counsel for appropriate vaccination administration

#### **COMPONENT 4 - REASSESSMENT AND PATIENT FOLLOW UP**

The fellow should be able to:

- 1. Reassess the patient over time, including recognition of treatment related adverse events, and alter the treatment plan accordingly.
- 2. Utilize the validated instruments in the assessment of pain, disease activity, function, and quality of life over time to monitor and adjust therapy
- 3. Address comorbid illness in patients with rheumatic diseases and incorporate these considerations into the care plan
- 4. Enumerate disease- and treatment-related complications that may lead to long term morbidity, considering implications of comorbid diseases and effects of aging

#### **III. PRACTICE-BASED LEARNING AND IMPROVEMENT**

The practice of rheumatology entails the assessment and treatment of patients with clinical disorders that are often complex with regard to the different organ systems involved, variations in musculoskeletal and immune system biology, and impact upon patient lifestyle and livelihood. The rapid advances in understanding and the complexity of both disease pathogenesis and treatment of the rheumatic diseases demand that the rheumatologist continually evaluate and improve the quality of his/her care in the context of his/her own clinical practice. The development of skills in self-directed, reflective learning and practice improvement will facilitate the delivery of state-of-the-art, evidence-based patient care that maximizes the likelihood for successful clinical outcomes.

#### DEFINITION

Practice-based learning and improvement involves the evaluation of care provided to both individual patients as well as to groups of patients in a given practice, the appraisal and assimilation of scientific evidence relevant to clinical problems encountered, evaluations of the care provided in the context of this evidence, and effecting improvements in patient care based upon these evaluations.

#### **ESSENTIAL COMPONENTS**

In addition to structured learning of the basic components of medical knowledge and patient care, the rheumatologist must evaluate his/her knowledge base and care delivery on an ongoing basis with the goal of continually improving that care. This process includes the following components:

- A. Independent Learning The fellow should be able to:
  - 1. Learn and improve at the point of care to enhance future clinical interactions
  - 2. Seek resources to enhance future clinical interactions.
  - 3. Recognize, and implement ways to improve his/her role in the effective management of a practice.
  - 4. Incorporate technology to manage information (HIPAA compliant), support patient care decisions using evidence-based medicine and enhance both patient and physician education
- B. Self-evaluation of performance The fellow should be able to:
  - 1. Monitor practice with goal for improvement
  - 2. Honestly reflect on knowledge, skills or attitude gaps to guide ongoing learning, using internal and external sources
  - 3. Actively seek, reflect on, and develop plans for practice improvement based on feedback from all members of the health care team including faculty, peers, students, health professionals, patients and patient advocates.
- C. Incorporation of feedback into improvement of clinical activity The fellow should be able to:
  - 1. Demonstrate that s/he learns from errors through actions taken to improve the system or processes of care.
  - 2. Display the ability to change practice based on an audit of a panel of patients using standardized, disease specific, and evidence based criteria.
  - 3. Independently construct and pursue answers to clinical questions, and perform self-reflection to incorporate learning for future clinical encounters.
  - 4. Demonstrate the ability to respond to meet situational needs, and customize management based on clinical evidence for individualized patient care.
- D. Incorporation of feedback into improvement of clinical activity The fellow should be able to:
  - 1. Demonstrate that s/he learns from errors through actions taken to improve the system or processes of care.

- 2. Display the ability to change practice based on an audit of a panel of patients using standardized, disease specific, and evidence based criteria.
- 3. Independently construct and pursue answers to clinical questions, and perform self-reflection to incorporate learning for future clinical encounters.
- 4. Demonstrate the ability to respond to meet situational needs, and customize management based on clinical evidence for individualized patient care.

#### **IV. SYSTEMS-BASED PRACTICE**

The increasing complexity and diversity of health care delivery systems presents both challenges and opportunities for the practice of rheumatology. Knowledge of the nature and variety of the external and internal systems that can impact clinical practice and the effective utilization of that knowledge to positively impact patient care is an essential skill. It is important for trainees to both recognize how their own practices intersect with others, and to work in teams to improve health care delivery.

The knowledge base of systems-based practice comprises the advantages and disadvantages of different health care systems that impact patients with rheumatic diseases. Some of these include the academic system in which rheumatology fellows are training, the various private and public health care delivery systems, the governmental agencies and programs that regulate these systems, the volunteer, private and governmental agencies that are available to educate and assist patients, the challenges faced by disabled patients negotiating these systems and the social and economic burden of chronic rheumatic diseases. The goal of the systems-based practice curriculum is to enhance the ability of rheumatology trainees to positively influence patient care by effectively utilizing these internal and external resources, to serve as effective advocates for their patients, and to provide cost-effective patient care. In some cases this may also mean identifying and organizing changes in the local systems' problems that can improve patient care.

#### DEFINITION

Systems-based practice reflects an understanding of and responsiveness to the larger context and system of health care, as well as the ability to call effectively on other resources in the system to provide optimal health care.

#### **ESSENTIAL COMPONENTS**

A. Partners in health care delivery: the various providers and resources available to deliver optimal care.

This partnership starts with coordinating both a multidisciplinary and interprofessional approach to patient-centered care. The principal partners in delivering health care to patients with rheumatic diseases include providers such as administrative and nursing staff, referring and consulting physicians, nurse practitioners, physician assistants and other health professionals participating in the local health care system. Partners also include outside volunteer agencies, both locally and nationally, such as the American College of Rheumatology, Association of Rheumatology Health Professionals, the Rheumatology Research Foundation, the Arthritis Foundation, the disease-specific foundations (including but not limited to Lupus, Scleroderma, Ankylosing Spondylitis, Vasculitis), the National Institute of Health (NIH) and its component institutes and pharmaceutical companies that have specific patient-related initiatives. Other agencies that have impact on the practice of rheumatology include the American Medical Association (AMA), the Food and Drug Administration (FDA) and the Center for Medicare and Medicaid Services (CMS).

Working within interprofessional and interdisciplinary teams, rheumatologists should work to promote patient safety. It is also important to identify risks for and strategies to prevent medical errors and to

address them appropriately if they occur.

B. Systems thinking: a concept of "systems thinking" in health care delivery

This includes an appreciation for the spectrum of practice models for health care delivery (academic/public/private/Veterans Affairs) including the fundamentals of office and personnel management, practice management strategies, managed care, health insurance, appropriate coding and reimbursement policies.

It also comprises an ongoing analysis of the limitations and opportunities within the local health care system, in both the inpatient and outpatient settings, and its impact on the health care delivery to patients with rheumatic diseases. In particular, efforts should be made to identify potentially correctable systems' weaknesses and medical errors due to systems' failures and to develop strategies to rectify the problems (i.e. quality improvement projects).

Systems thinking includes implementing strategies to coordinate care and transition patients safely and efficiently across multiple delivery systems, including ambulatory, sub-acute, acute, rehabilitation and skilled nursing facilities.

C. Advocacy for the patient: the importance, opportunities and limits of patient advocacy

This advocacy includes assisting patients with applications for medical disability determinations, completing preauthorization documents for the use of certain medications and appealing to insurance companies with respect to denial of certain treatments, benefits and claims.

It is also important to recognize opportunities to address disparities in disease and in health care delivery impacting patient care, including socio-economic factors, health care literacy, medical disability and health care insurance coverage.

Activities may include broader advocacy for populations on a local, state or national level.

D. Cost-effective health care: the principles of cost allocation and resource management within the external (state, national) and local systems

The delivery of cost-effective health care includes realizing how the cost and availability of certain diagnostic tests, drugs and other therapies impact patient care. The utilization of evidence-based cost-conscious best practice strategies for the diagnosis and treatment of patients with rheumatic diseases is paramount.

#### **V. INTERPERSONAL AND COMMUNICATION SKILLS**

Interpersonal and communication skills are essential for the formation of a desirable and effective physicianpatient relationship. The complexity of most of the rheumatic diseases, as well as the increasingly complicated treatment regimens, require a working partnership between patient and physician, and often between both physician and the patient's family or caregiver(s), as well as physician and members of an interprofessional team of providers. In addition to improved patient satisfaction, confidence and understanding, such working partnerships promote medical compliance. Effective physician collegial relationships are also dependent upon these skills.

#### DEFINITION

Interpersonal and communication skills that result in the effective exchange of information and collaboration with patients, their families, and other health professionals.

#### **ESSENTIAL COMPONENTS**

- A. Gathering information Reliable and effective communication depends upon the availability of accurate and complete information obtained from patients, their families, other health professionals, and the complete medical record. This requires the use of effective listening and communication skills.
- B. Recognizing and incorporating the patient's perspective Such understanding impacts the ability of the physician to appreciate the functional impact of disease and the desire and ability of the patient to be an active partner in decision-making and treatment efforts. Evaluation and management plans should demonstrate sensitivity to, and integrate differences in patient characteristics.
- C. Providing information

Communication regarding disease manifestations, diagnosis and treatment is only effective if the recipient has gained appropriate understanding of the information at the end of the exchange. Effective explanation and documentation therefore require that the physician communicate in a manner that is clear and is adjusted to the specific context, situation, and/or audience.

D. Trust

Establishment of trust with the patient, the patient's family or caregiver(s), and other health professionals is paramount.

#### **VI. PROFESSIONALISM**

Professionalism is one of the foundations of the practice of medicine. By virtue of their prior medical school education and internal medicine training, rheumatology fellows have typically already attained a substantial level of professionalism, which can be further enriched during the fellowship training period. The complexity of rheumatic diseases and their management requires effective interactions between rheumatology trainees and referring providers, subspecialty consultants, other health care providers, hospital administrators and health insurance representatives in providing care for their patients. Trainees in many programs interact with patients from a wide range of cultural and socioeconomic backgrounds. In addition, fellows must learn to recognize and manage potential conflicts of interest with professional activities as well as with pharmaceutical companies (i.e. clinical research trials, pharmaceutical company interactions, grant review processes). A high level of professionalism is thus essential to maintain the balance required be an effective rheumatologist.

#### DEFINITION

Professionalism is manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to patients of diverse backgrounds.

#### ESSENTIAL COMPONENTS

A. Primacy of patient interest

Placing the interest of the patient before all other external interests is the most fundamental aspect of the medical profession and forms part of the unwritten contract in the patient-physician relationship. This primacy also implies patient autonomy in the determination of treatment. As a demonstration of patient advocacy, the fellow needs to respond to each patient's unique characteristics and needs. This includes but is not limited to:

- 1. Demonstrating empathy and compassion to all patients,
- 2. Addressing disparities in health care that may impact patient care, and
- 3. Taking responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases).
- B. Physician responsibility and accountability

The practice of medicine incurs responsibility and accountability to patients, colleagues, society, and self. The physician must maintain professional and respectful interactions with patients, caregivers, and members of the interprofessional team (e.g., peers, consultants, nursing, ancillary professionals, and support personnel).

- 1. To demonstrate commitment to providing safe patient care, the physician must recognize, respond to, and report either the impairment in colleagues, or the provision of substandard care, via a peer review process.
- 2. To demonstrate the professional attribute of accessibility, the physician accepts responsibility and follows through on tasks, including but not limited to completion of clinical, administrative, curricular and research-related tasks.
- 3. To demonstrate the professional attribute of personal accountability, the physician should contribute to the fiscally sound practice of medicine.
- 4. Physicians should responsibly use technology and social media.
- 5. To manage conflicts of interest the physician must maintain ethical relationships with patients, colleagues, members of the interprofessional team, office staff and industry.
- C. Humanistic qualities and altruism

Physicians should treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs.

1. To demonstrate compassion and respect to patients and their caregivers, physicians should endeavor to support patients' needs (physical, psychological, social, and spiritual)

#### D. Ethical behavior

The physician must exhibit integrity and ethical behavior in professional conduct.

- 1. This includes, but is not limited to, accepting personal errors and honestly acknowledging them, maintaining patient confidentiality, upholding ethical expectations of clinical, scholarly and research activities, as well as maintenance of credentialing requirements.
- 2. The physician must address personal, psychological, and physical limitations that may affect professional performance.
- 3. Integrity must pervade all of the components of professionalism.

### **APPENDICES**

APPENDIX A. RHEUMATOLOGY MILESTONES 2.0



## **Rheumatology Milestones**

The Accreditation Council for Graduate Medical Education



Second Revision: August 2020 First Revision: October 2014

### **Rheumatology Milestones**

The Milestones are designed only for use in evaluation of fellows in the context of their participation in ACGMEaccredited residency or fellowship programs. The Milestones provide a framework for the assessment of the development of the fellow in key dimensions of the elements of physician competence in a specialty or subspecialty. They neither represent the entirety of the dimensions of the six domains of physician competence, nor are they designed to be relevant in any other context.

#### **Rheumatology Milestones Work Group**

Michael Battistone, MD Marcy B. Bolster, MD Anisha Dua, MD, MPH Laura Edgar, CAE, EdD Karen Gouze, PhD Jason Kolfenbach, MD Jason Liebowitz, MD Bethany Marston, MD Kevin McKown, MD Kenneth O'Rourke, MD Karina Torralba, MD, MACM, RhMSUS, CCD Joanne Valeriano-Marcet, MD

# The ACGME would like to thank the following organizations for their continued support in the development of the Milestones:

American Board of Internal Medicine American College of Rheumatology Review Committee for Internal Medicine

#### **Understanding Milestone Levels and Reporting**

This document presents the Milestones, which programs use in a semi-annual review of fellow performance, and then report to the ACGME. Milestones are knowledge, skills, attitudes, and other attributes for each of the ACGME Competencies organized in a developmental framework. The narrative descriptions are targets for resident/fellow performance throughout their educational program.

Milestones are arranged into levels. Tracking from Level 1 to Level 5 is synonymous with moving from novice to expert fellow in the specialty or subspecialty. For each reporting period, the Clinical Competency Committee will review the completed evaluations to select the milestone levels that best describe each learner's current performance, abilities, and attributes for each subcompetency.

These levels *do not* correspond with post-graduate year of education. Depending on previous experience, a junior fellow may achieve higher levels early in his/her educational program just as a senior fellow may be at a lower level later in his/her educational program. There is no predetermined timing for a resident to attain any particular level. Fellows may also regress in achievement of their milestones. This may happen for many reasons, such as over scoring in a previous review, a disjointed experience in a particular procedure, or a significant act by the fellow.

Selection of a level implies the fellow substantially demonstrates the milestones in that level, as well as those in lower levels (see the diagram on page vi).

#### **Additional Notes**

Level 4 is designed as a graduation *goal* but *does not* represent a graduation *requirement*. Making decisions about readiness for graduation and unsupervised practice is the purview of the program director. Furthermore, Milestones 2.0 include revisions and changes that preclude using Milestones as a sole assessment in high-stakes decisions (i.e., determination of eligibility for certification or credentialing). Level 5 is designed to represent an expert fellow whose achievements in a subcompetency are greater than the expectation. Milestones are primarily designed for formative, developmental purposes to support continuous quality improvement for individual learners, education programs, and the specialty. The ACGME and its partners will continue to evaluate and perform research on the Milestones to assess their impact and value.

Some milestone descriptions include statements about performing independently. These activities must occur in conformity to ACGME supervision guidelines as described in the Program Requirements, as well as to institutional and program policies. For example, a fellow who performs a procedure independently must, at a minimum, be supervised through oversight.

A Supplemental Guide is also available to provide the intent of each subcompetency, examples for each level, assessment methods or tools, and other available resources. The Supplemental Guide, like examples contained within the Milestones, is designed only to assist the program director and Clinical Competency Committee, and is not meant to demonstrate any required element or outcome.

Additional resources are available in the <u>Milestones</u> section of the ACGME website. Follow the links under "What We Do" at <u>www.acgme.org</u>.

The diagram below presents an example set of milestones for one sub-competency in the same format as the ACGME Report Worksheet. For each reporting period, a fellow's performance on the milestones for each subcompetency will be indicated by selecting the level of milestones that best describes that fellow's performance in relation to those milestones.

Level 1	Level 2	Level 3	Level 4	Level 5
Establishes personal and professional goals, identifying gap(s) between goals and current performance	Demonstrates receptiveness to feedback, analyzing and reflecting on factors contributing to gap(s) between goals and current performance	Seeks feedback episodically, and institutes behavioral change(s) when necessary	Seeks feedback consistently, and sustains behavioral change as necessary	Role models consistently seeking performance data with adaptability and humility, and coaches others on reflective practice
	Designs and implements a learning plan, with prompting	Independently creates and implements an individualized learning plan	Uses performance data to measure the effectiveness of the learning plan and when necessary, improves it	Facilitates the design and implementing learning plans for others
Comments:				
Selecting a response box in the middle of a level implies that milestones in that level and in lower levels have been substantially demonstrated.		between level in lower level demonstrated	esponse box on the line i ils indicates that milestor s have been substantially d as well as <b>some</b> the higher level(s).	nes

#### Practice-Based Learning and Improvement 2: Commitment to Reflective Practice and Personal Growth

©2020 Accreditation Council for Graduate Medical Education (ACGME)

All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes.

Patient Care 1: Gathers an Essential and Accurate Patient History				
Level 1	Level 2	Level 3	Level 4	Level 5
Acquires a basic rheumatic history Reviews available medical records	Integrates a rheumatic history with a comprehensive medical history, including functional aspects Identifies relevant findings in the medical record	Acquires a tailored comprehensive rheumatic history, including historical subtleties and psychosocial aspects Independently requests additional information to supplement available medical records	Integrates the current patient history with the complete medical record, supplemental information, and disease activity measures	Identified as a role model in interpreting subtleties and resolving ambiguities in the patient history
Comments: Not Yet Completed Level 1				

Patient Care 2: Physical Examination				
Level 1	Level 2	Level 3	Level 4	Level 5
Identifies the elements of a comprehensive physical examination	Performs all elements of a comprehensive physical examination	Performs a tailored comprehensive physical examination including advanced techniques, when applicable	Performs a tailored comprehensive physical examination that elicits subtle findings	Identified as a role model for performing and interpreting a comprehensive, accurate physical and musculoskeletal examination
Identifies the elements of a musculoskeletal examination	Performs all elements of a musculoskeletal examination	Performs a tailored comprehensive musculoskeletal examination including advanced techniques, when applicable	Performs a tailored comprehensive musculoskeletal examination that elicits subtle findings	
Comments: Not Yet Completed Level 1				

Patient Care 3: Comprehensive Management Plan Development				
Level 1	Level 2	Level 3	Level 4	Level 5
With supervision, formulates a differential diagnosis for a patient	Independently formulates a broad differential diagnosis for typical disease presentations	Independently formulates a prioritized differential diagnosis for typical disease presentations	Independently formulates a prioritized differential diagnosis with consideration of typical and atypical disease presentations	Independently formulates a prioritized differential diagnosis with consideration of newly recognized and emerging conditions
Demonstrates an awareness of disease activity measures With supervision, develops a management plan	Identifies applicable disease activity measures Independently develops a management plan for a patient with common disease presentations	Incorporates and interprets the results of disease activity measure Independently recognizes disease acuity, and with supervision, develops a prioritized management plan	Independently develops and implements a prioritized management plan with consideration of acuity and complexity of disease presentation	Identified as an expert resource for management of a focused disease area
Comments:       Not Yet Completed Level 1 <ul> <li>Not Yet Assessable</li> <li>Image: Second sec</li></ul>				

Patient Care 4: Therapeutics, including Immunomodulatory Agents					
Level 1	Level 2	Level 3	Level 4	Level 5	
Identifies indications and adverse effects of medications used to treat patients with common rheumatic conditions	Prescribes and monitors medications used in patients with common rheumatic conditions	Prescribes, monitors, and assesses the response to pharmacotherapy used in the management of patients with common rheumatic conditions	Integrates best available evidence to prescribe, monitor, and assess the response to pharmacotherapy used in the management of patients with common and complex rheumatic conditions	Develops a clinical practice pathway for management of patients with rheumatic conditions	
	Evaluates for comorbidities that may alter therapeutic recommendations	Modifies treatment plans to address comorbidities, with supervision	Independently modifies treatment plans to address comorbidities		
Comments: Not Yet Completed Level 1  Not Yet Assessable					

Patient Care 5: Procedures				
Level 1	Level 2	Level 3	Level 4	Level 5
Identifies indications for joint and soft tissue aspirations and injections, and discusses principles of informed consent	Performs common joint and soft tissue injections and aspirations with direct supervision, including independently discussing risks and benefits, obtaining informed consent, identifying anatomic landmarks, and demonstrating aseptic technique	Performs common joint and soft tissue aspirations and injections with indirect supervision	Independently performs common joint and soft tissue aspirations and injections	Independently performs complex joint and soft tissue aspirations or injections, including unusual sites, anatomic abnormalities, or incorporating imaging guidance
	Recognizes the role of musculoskeletal ultrasound in the diagnosis and treatment of patients with rheumatic conditions	Interprets the findings of musculoskeletal ultrasound for common conditions with supervision	Independently interprets the findings of musculoskeletal ultrasound for common conditions, and recognizes the role of ultrasound in non- musculoskeletal rheumatic conditions	Independently performs and interprets point-of- care diagnostic ultrasound and uses ultrasound to guide invasive procedures
Comments:				
Comments.			Not Yet Co Not Yet As	ompleted Level 1     Impleted Level 1       ssessable     Impleted Level 1

Level 1	Level 2	Level 3	Level 4	Level 5
Respectfully receives a consultation request	Clearly and concisely responds to a consultation request	Verifies understanding of recommendations with the primary team when providing consultation	Integrates recommendations from different members of the health care team and effectively conveys consultative assessment and rationale to all health care team members	Identified as a role model for the provision of consultative care across the spectrum of disease complexity and acuity
With supervision, recognizes disease acuity	Independently recognizes disease acuity	Recognizes disease acuity and prioritizes management steps	Mobilizes resources to provide care in high- acuity situations	
Comments:   Not Yet Completed Level 1   Not Yet Assessable				

Medical Knowledge 1: Possesses Clinical Knowledge				
Level 1	Level 2	Level 3	Level 4	Level 5
Identifies key features of common rheumatic conditions	Demonstrates broad knowledge of common rheumatic conditions	Demonstrates knowledge of less common rheumatic conditions as well as common rheumatic conditions associated with higher complexity	Integrates knowledge of the pathogenesis, epidemiology, clinical expression, treatments, and prognosis of a broad range of rheumatic conditions	Identified as a subject matter expert in basic and/or clinical science of
Demonstrates basic knowledge of anatomy, physiology, and other basic sciences	Demonstrates basic knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to rheumatic conditions	Demonstrates in-depth knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to rheumatic conditions	Integrates knowledge of anatomy, genetics, immunology, metabolism, and other basic sciences pertaining to a broad range of rheumatic conditions	rheumatic conditions
Comments: Not Yet Completed Level 1				

Medical Knowledge 2: Knowledge of Diagnostic Testing					
Level 1	Level 2	Level 3	Level 4	Level 5	
Explains the rationale, risks, and benefits for common diagnostic testing in patients being evaluated for rheumatic conditions	Integrates value and test characteristics into diagnostic strategies in patients with uncomplicated rheumatic conditions	Integrates value and test characteristics into diagnostic strategies in patients with complex rheumatic conditions	Integrates and reconciles information, including non-specific and/or conflicting diagnostic test results to form a cohesive evaluation	Identified as an expert in testing strategies and in the selection and interpretation of complex, new, or emerging tests	
Comments: Not Yet Completed Level 1					
			Not Yet As	ssessable	

Medical Knowledge 3: Scholarly Activity					
Level 1	Level 2	Level 3	Level 4	Level 5	
Identifies areas worthy of scholarly investigation, with supervision	Designs a scholarly activity with a mentor(s)	Engages in scholarly work, incorporates feedback, and participates in critical appraisal and analysis of project data	Produces scholarly work suitable for dissemination as an abstract or presentation	Dissemination of independent scholarly work that has generated new medical knowledge, educational programs, or process improvement	
Comments:			Not Yet C Not Yet A	ompleted Level 1	

Level 1	Level 2	Level 3	Level 4	Level 5
Demonstrates knowledge of common patient safety events	Identifies system factors that lead to patient safety events	Participates in analysis of patient safety events (simulated or actual)	Conducts analysis of patient safety events and offers error prevention strategies (simulated or actual)	Actively engages teams and processes to modify systems to prevent patient safety events
Demonstrates knowledge of how to report patient safety events	Reports patient safety events through institutional reporting systems (actual or simulated)	Participates in disclosure of patient safety events to patients and families (simulated or actual)	Discloses patient safety events to patients and families (simulated or actual)	Role models or mentors others in the disclosure of patient safety events
Demonstrates knowledge of basic quality improvement methodologies and metrics	Describes quality improvement initiatives relevant to rheumatology practice	Participates in quality improvement initiatives relevant to rheumatology practice	Demonstrates the skills required to identify, develop, implement, and analyze a quality improvement project	Creates, implements, and assesses quality improvement initiatives at the institutional or community level

Demonstrates	Coordinates care of			
nowledge of care coordination	patients in routine clinical situations effectively using the roles of the interprofessional teams	Coordinates care of patients in complex clinical situations effectively using the roles of their interprofessional teams	Role models effective coordination of patient- centered care among different disciplines and specialties	Leads in the design and implementation of improvements to the care coordination process
dentifies key elements or safe and effective ransitions of care and and-offs	Performs safe and effective transitions of care/hand-offs in routine clinical situations	Performs safe and effective transitions of care/hand-offs in complex clinical situations	Role models and advocates for safe and effective transitions of care/hand-offs within and across health care delivery systems including outpatient settings	Improves quality of transitions of care within and across health care delivery systems to optimize patient outcomes
Demonstrates nowledge of population and community health needs and disparities	Identifies specific population and community health needs and inequities for their local population	Uses local resources effectively to meet the needs of a patient population and community	Participates in changing and adapting practice to provide for the needs of specific populations	Leads innovations and advocates for populations and communities with health care inequities

©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes

Systems-Based Practice 3: Physician Role in Health Care Systems					
Level 1	Level 2	Level 3	Level 4	Level 5	
Identifies key components of the complex health care system (e.g., hospital, skilled nursing facility, finance, personnel, technology)	Describes how components of a complex health care system are interrelated, and how this impacts patient care	Discusses how individual practice affects the broader system (e.g., length of stay, readmission rates, clinical efficiency)	Manages various components of the complex health care system to provide efficient and effective patient care and transition of care	Advocates for or leads systems change that enhances high-value, efficient, and effective patient care and transition of care	
Recognizes the impact of cost and patient payment model on care decisions	Identify the principles of high-value care and delivers care with consideration of each patient's payment model	Engages with patients in shared decision making and incorporates principles of high-value care into management plans	Advocates for individual patient care needs to provide high-value care	Participates in health policy advocacy activities	
	Demonstrates use of information technology (e.g., electronic health record) needed for clinical practice	Demonstrates knowledge of current evaluation and management billing practices	Independently completes proper documentation and coding for a patient encounter	Educates others on proper documentation, billing, and coding practices	
Comments:	Comments:				

©2020 Accreditation Council for Graduate Medical Education (ACGME) All rights reserved except the copyright owners grant third parties the right to use the Rheumatology Milestones on a non-exclusive basis for educational purposes

Practice-Based Learning and Improvement 1: Evidence-Based and Informed Practice				
Level 1	Level 2	Level 3	Level 4	Level 5
Formulates clinical questions and elicits patient preferences to inform care	Locates available evidence and incorporates patient preferences to inform patient care	Evaluates and applies best available evidence and incorporates patient preferences and values in order to provide care tailored to individual patients	Critically appraises and applies evidence, and recognizes gaps and conflicting evidence to guide care tailored to individual patients	Coaches others to critically appraise and apply evidence for complex patients; and/or participates in the development of guidelines
Comments:				

Level 1	Level 2	Level 3	Level 4	Level 5
Establishes personal and professional goals, identifying gap(s) between goals and current performance	Demonstrates receptiveness to feedback, analyzing and reflecting on factors contributing to gap(s) between goals and current performance	Seeks feedback episodically, and institutes behavioral change(s) when necessary	Seeks feedback consistently, and sustains behavioral change as necessary	Role models consistently seeking performance data with adaptability and humility, and coaches others on reflective practice
	Designs and implements a learning plan, with prompting	Independently creates and implements an individualized learning plan	Uses data and feedback from multiple sources to measure the effectiveness of the learning plan and when necessary, improves it	Facilitates the design and the implementation of learning plans for others

Professionalism 1: Professional Behavior				
Level 1	Level 2	Level 3	Level 4	Level 5
Describes when and how to appropriately report professionalism lapses, including strategies for addressing common barriers	Identifies and describes triggers for professionalism lapses and takes responsibility for own professional behavior	Proactively recognizes situations that may trigger professionalism lapses	Demonstrates professional behavior in complex or stressful situations and intervenes to prevent lapses in self and others	Coaches others when behavior fails to meet professional expectations
Comments:				

Professionalism 2: Ethical Principles						
Level 1	Level	Level 3	Level 4	Level 5		
Demonstrates knowledge of basic ethical principles	Applies basic principles to resolve straightforward ethical situations	Analyzes complex situations using ethical principles and recognizes need to seek help in resolving complex ethical situations	Manages and resolves complex ethical dilemmas using available resources	Identifies and seeks to address system-level factors that induce or exacerbate ethical problems or impede their resolution		
Comments:			Not Yet C	ompleted Level 1		

Professionalism 3: Accountability/Conscientiousness						
Level 1	Level 2	Level 3	Level 4	Level 5		
Performs tasks and responsibilities, with prompting	Performs tasks and responsibilities in a timely manner with attention to detail in routine situations	Performs tasks and responsibilities in a timely manner with attention to detail in complex or stressful situations	Demonstrates leadership to ensure tasks and responsibilities are completed in a timely manner with attention to detail in complex or stressful situations	Creates strategies to enhance others' ability to efficiently complete tasks and responsibilities		
Takes responsibility for failure to complete tasks and responsibilities	Recognizes situations that may impact own ability to complete tasks and responsibilities in a timely manner	Recognizes situations that may impact others' ability to complete tasks and responsibilities in a timely manner	Proactively implements strategies to ensure that the needs of patients, teams, and systems are met			
Comments: Not Yet Completed Level 1						

Professionalism 4: Self-Awareness and Help-Seeking						
Level 1	Level 2	Level 3	Level 4	Level 5		
Recognizes status of own and others' well- being, with assistance	Independently recognizes status of own and others' well-being, and asks for help when needed	Recognizes the impact of own and others' well- being on the patient and team, with assistance	Independently recognizes the impact of own and others' well- being on the patient and team, and asks for help when needed	Leads initiatives to improve wellness at the program or institutional level		
With assistance recognizes personal gaps in knowledge, skills, and attitudes	Independently recognizes limits in personal knowledge, skills, and attitudes	With assistance, develops a plan to improve personal knowledge, skills, and attitudes	Independently implements a plan to improve personal knowledge, skills, and attitudes	Coaches others when limitations in knowledge, skills, and attitudes do not meet professional expectations		
Comments: Not Yet Completed Level 1						

Level 1	Level 2	Level 3	Level 4	Level 5	
Uses language and nonverbal behavior to demonstrate respect and establish rapport	Establishes a therapeutic relationship with the patient in uncomplicated clinical encounters using active listening and clear language	Establishes a therapeutic relationship with the patient in challenging clinical encounters	Consistently establishes and maintains therapeutic relationships using shared decision making	Serves as a role model in establishing respectful, culturally sensitive	
Recognizes common barriers to effective communication (e.g., language, disability) while accurately communicating own role within the health care system	Recognizes complex barriers to effective communication (e.g., health literacy, cultural competency)	Adjusts communication strategies based on identified barriers, incorporating patient and caregiver expectations and goals of care	Uses self-reflection to proactively minimize communication barriers	therapeutic relationships while mitigating communication barriers	
Comments:					

Level 1	Level 2	Level 3	Level 4	Level 5
Uses language that is respectful and values all members of the health care team	Communicates basic information effectively with all health care team members	Communicates highly complex information effectively with all health care team members	Optimizes flexible communication strategies using input from all team members to build consensus and resolve conflicts, as needed	Demonstrates leadership in promoting open and safe communication within and between teams
Accepts feedback from team members	Solicits feedback on performance as a member of the health care team	Provides feedback to peers and other learners on the team	Communicates detailed and effective feedback to any member of the health care team	Educates others in providing effective feedback

Level 1	Level 2	Level 3	Level 4	Level 5
Accurately records information in the patient record	Demonstrates organized diagnostic and therapeutic reasoning through notes in the patient record	Concisely reports diagnostic and therapeutic reasoning in the patient record	Communicates clearly, concisely, timely, and in an organized written form, including anticipatory guidance	
Safeguards patient personal health information in direct (e.g., telephone, in- person) and indirect (e.g., progress notes, text messages) communications	Accurate and timely documentation with appropriate use of documentation tools	Appropriately selects direct and indirect forms of communication based on context	Produces written or verbal communication (e.g., patient notes, email) that could serve as an example for others to follow	Participates in establishing communication tools or policies for the division, department, or institution

## APPENDIX B. RHEUMATOLOGY ENTRUSTABLE PROFESSIONAL ACTIVITES



Empowering Rheumatology Professionals

## Adult Rheumatology Entrustable Professional Activities (EPA)

Approved by the American College of Rheumatology

- 1. Manage the care of patients with acute and chronic, common and complex rheumatologic diseases across multiple care settings. *MK*, *PC*, *ICS*, *P*, *PBLI*, *SBP*
- 2. Demonstrate expertise in the performance and interpretation of the musculoskeletal examination. *MK, PC, ICS, P*
- Demonstrate expertise in the indications for and interpretation of diagnostic tests and imaging studies relevant to the evaluation of patients with suspected or established rheumatic and musculoskeletal disease.
   MK, PC, ICS, P
- 4. Prescribe and manage immunomodulatory therapy. *MK, PC, ICS, P, PBLI, SBP*
- Perform procedures including arthrocentesis and injections, compensated polarized microscopy, and interpretation of synovial fluid analysis. MK, PC, ICS, P, PBLI
- 6. Provide rheumatology consultation to other specialties and providers. *MK, PC, ICS, P, PBLI, SBP*
- 7. Demonstrate professional, compassionate and ethical behavior. ICS, P
- 8. Effectively communicate and manage transitions of care with other healthcare providers. *MK, PC, ICS, P*

- 9. Collaborate and work effectively as a member or leader of interprofessional health care teams. *MK, PC, ICS, P, PBLI, SBP*
- 10. Facilitate the learning of patients, families, and members of the interprofessional team. MK, PC, ICS, P
- Enhance and promote patient safety and the quality of health care at both the individual and systems level. *MK, PC, ICS, P, PBLI, SBP*
- 12. Advocate for individual patients. *MK, PC, ICS, P, SBP*
- 13. Contribute to the fiscally sound and ethical management of a practice. *PC, ICS, P, SBP*
- 14. Engage in lifelong learning. *MK, PBLI, SBP*

## APPENDIX C. RHEUMATOLOGY CURRICULAR MILESTONES

1. Gathers and	synthesizes essential ar	nd accurate information	to define each patient's	clinical problem(s). (PC	1)
		Rheumatolog	y Curricular Milestones		
Number		By the listed time the f	ellow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular innestone
PC1-01	Obtain and report	Formulate with relevance	Incorporate; Teach others the elements of		a comprehensive, accurate history, including review of all available records, on
					patients with rheumatic symptoms and signs.
	Perform a	and report	Distinguish with relevance; Integrate	Teach others to perform	a comprehensive, accurate physical examination, using
PC1-02					common and advanced techniques where applicable,
		on patients with rheumatic symptoms and signs.			
	Order and review	Interpret	Incorporate	Teach others about the clinical application of	diagnostic tests including, but not limited to,
DC1 02					laboratory, imaging, electrodiagnostic and
PC1-03					pathologic studies for the evaluation of the patient
					with rheumatic symptoms and signs.
	List the steps of	Recognize normal anatomy	Differentiate abnormal findings	Teach others to detect abnormalities	using a standardized approach to the
PC1-04					interpretation of musculoskeletal plain
					radiographs.
	Describe applications, in	dications and limitations	Recognize normal anatomy; Di	fferentiate abnormal findings	using a standardized approach for the
PC1-05					interpretation of musculoskeletal
					ultrasonography for diagnostic purposes.

	Recognize the need to	Without faculty member	collaboratively review
		prompting,	imaging and tissue
PC1-06			specimens with radiology
PC1-00			and pathology services,
			respectively, to enhance
			patient safety and care

2. Develops an	2. Develops and achieves comprehensive management plan for each patient. (PC2)					
		Rheumatolog	y Curricular Milestones			
Number		By the listed time the f	ellow should be able to		For this curricular milestone	
Number	6 months	12 months	18 months	24 months	For this curricular milestone	
PC2-01	List the components of	For uncomplicated presentations construct and implement	For complicated presentations construct and implement	Teach others to formulate	a comprehensive treatment plan, based on clinical evidence, clinical context,	
PC2-01					and patient preferences, counsel patients, and assess response to therapy.	
PC2-02	Describe state and federal regulations for prescription of controlled substances as part of	Describe non-pharmacologic and pharmacologic components of; Implement, and monitor response to therapy, patient compliance, and detect signs and symptoms indicative of analgesic abuse as part of			a pain management strategy of the care plan.	
PC2-03	Describes indications and potential adverse events of	Obtains verbal or written informed consent for treatment with	Prescribe, monitor and assess response to	Teaches others to prescribe, monitor and assess response to	pharmacotherapy, including immunomodulatory agents, used in the management of	
					patients with rheumatic diseases.	
PC2-04	In comparison to adults, discuss the similarities and differences in drug disposition and its consequences regarding; List the currently used		Prescribe and adj	just accordingly	pharmacotherapies for use in children and adolescents with rheumatic diseases.	
PC2-05	_	pharmacokinetics that occur e affect	Prescribe and adjust appropriately	Teach others about	therapeutic and management strategies in	
					the aging population with	

					rheumatic diseases.
PC2-06	List options for	Describe applications and indications for	Incorporate	Teach others to incorporate	exercise and other rehabilitation strategies in
PC2-06					the care of patients with rheumatic disorders.
	With attending supervision	With attending supervision for complicated presentations	Indepen Teach ot		formulate and implement a management plan for patients with rheumatic
PC2-07					emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care.

8. Manages patients with progressive responsibility and independence. (PC3)					
		Rheumatolog	y Curricular Milestones		
Number		By the listed time the f	fellow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular innestone
PC3-01	Describe the potential manifestations of	Formulate plans to screen for and manage	Implement and monitor plans for	Teach others to recognize and manage	disease-related exacerbations and the influence of comorbid illness during the provision of longitudinal and customized care to patients with rheumatic diseases.
PC3-02	Identify	Formulate plans to screen, assess severity, and manage	Implement and monitor plans to screen, assess severity, and manage	Teach others to recognize and manage	disease- and treatment- related complications that may lead to long term morbidity, including the consideration for implications of comorbid diseases and the effects of aging.
PC3-03	Recognize	Develop strate	egies to manage	Implement strategies to manage	the psychosocial aspects of rheumatic diseases.
PC3-04	List and describe the utility of	Incorporate into practice	Teach others to incor	porate into practice	the varied validated instruments in the assessment of pain, disease

4a. Demonstrates skill in performing and interpreting invasive procedures. (PC4a) NOTE: PC4a and PC4b (non-invasive						
procedures) converted to single template of Skill in performing procedures						
Rheumatology Curricular Milestones						
Number		By the listed time the fe	llow should be able to	-	For this curricular milestone	
Number	6 months	12 months	18 months	24 months	For this curricular innestone	
PC4-01	With attending supervision	Independently; Teach others to			obtain verbal or written informed consent from	
10401			]		patient or caregiver for procedures.	
PC4-02	With attending supervision	With attending assistance for previously u		Independently; Teach others to	perform procedures including arthrocentesis and	
PC4-02					joint and soft tissue injections.	
PC4-03	With attend	perform procedures including arthrocentesis and joint and soft tissue injections with ultrasound				
					guidance, when appropriate and feasible.	
PC4-04	With attending supervision	Independently	Teach others to		perform compensated polarized microscopy to examine and interpret synovial fluid.	

<b>Requests</b> a	nd provides consultative	care. (PC5)								
	Rheumatology Curricular Milestones									
Number		By the listed time the f	ellow should be able to		For this curricular mileston					
Number	6 months	12 months	18 months	24 months	For this curricular mileston					
PC5-01	Identify the indications to	Proactively	Teach others why, when, and how to		refer to other healthcare providers for the co-					
PC3-01					management of patients with rheumatic disease.					
PC5-02	Recognize the tissues commonly considered for	List the indications, expected risks and benefits, and available alternatives for	Implement plans to refer for; Teach others how to incorporate		diagnostic biopsies (including, but not limited to temporal artery, renal, lung					

									muscle, nerve, skin, minor salivary gland, and brain) in the evaluation of rheumatic diseases, and refers when indicated and appropriate.
		Identify	opportunities fo	or referral		Ref	er when indica	ted	to clinical registries and
PC5-03									trials.
	With attending supervis	sion			Independently				provide consultation when
									requested, in support of the
									primary care relationship, for patients with rheumatic
									symptoms and signs and
									symptoms and signs and
PC5-04									appropriately integrate
PC5-04									appropriately integrate recommendations from
PC5-04									appropriately integrate

6. Possesses Cl	inical knowledge (MK1)				
		Rheumatolog	y Curricular Milestones		
Number		By the listed time the f	fellow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular innestone
	Demonst	rate basic	Demonstrate co	omprehensive	knowledge of the relevant
MK1-01					structure and function of the musculoskeletal system, immune system and basic science for describing the pathophysiology of rheumatologic conditions.
MK1-02	Acknowledge the indications for	Independently distinguish indications for	Independently formulate specific consultative questions for		referrals to other subspecialists and ancillary services including orthopedics and rehabilitation medicine.

MK1-03	List Explain	Differentiate subtle differences in	relevant mechanisms of action and potential adverse effects of agents used in the management of patients with rheumatologic conditions.
MK1-04	Report on		the anatomy, physiology and management of pain in patients with rheumatologic conditions.
MK1-05		Describe in detail Explain the significance of	similarities and differences of the clinical presentation and management between adults and children with rheumatic conditions.
MK1-06	In uncomplicated cases, construct	In highly complex cases, with multi-system involvement, construct	a differential diagnosis for rheumatologic conditions, including consideration of non-rheumatic diseases.
MK1-07	Demonstrate basic	Demonstrate comprehensive	knowledge regarding the need for preventive care in patients with rheumatic conditions.
MK1-08	Demonstrate basic	Demonstrate comprehensive	knowledge to evaluate complex rheumatic diseases in the setting of multiple coexistent conditions, including the effects of aging.
MK1-09	Demonstrate basic	Demonstrate comprehensive	knowledge of socio- behavioral sciences including but not limited to health care economics and medical ethics.

7. Knowledge o	7. Knowledge of diagnostic testing and procedures. (MK2)								
	Rheumatology Curricular Milestones								
Number	By the listed time the fellow should be able to								
Number6 months12 months18 months24 monthsFor this curricular milester									

	Identify	C	escribe	Dif	ferentiate	Tea	ch	indications, risks and
		]						benefits of rheumatologic
								diagnostic testing, including but not limited to
								immunoassays, synovial fluid
MK2-01								analysis, routine blood
								chemistries, hematologic
								studies, coagulation studies,
								radiographs, and DXA
								scanning.
		Explai	n 📃 🗌			Teach others ab	out	 major findings and
								interpretation of rheumatologic diagnostic
								testing, including but not
								limited to immunoassays,
MK2-02								synovial fluid analysis,
								routine blood chemistries,
								hematologic studies, coagulation studies,
								radiographs, and DXA
								scanning.
	List	t		Explain			Differentiate	indications, risks and
		]						benefits for more advanced
								diagnostic tests including imaging techniques (isotopic,
								PET, CT and MRI scanning,
MK2-03								angiography and
								musculoskeletal ultrasound)
								and pathologic examination
								of tissues involved with rheumatic diseases.
		Explai	n			Teach others		major findings and
			<u></u>					interpretation of more
								advanced diagnostic tests
								including imaging techniques
MK2-04								(isotopic, PET, CT and MRI
								scanning, angiography and musculoskeletal ultrasound)
								and pathologic examination
								of tissues involved with
								of tissues involved with

8. Scholarship	. (MK3)				
		Rheumatolog	y Curricular Milestones		
Number		For this curricular milestone			
Number	6 months	12 months	18 months	24 months	
N4//2 04	Demonstrate basic		Demonstrate comprehensive		knowledge of principles
MK3-01					underlying critical appraisal of the medical literature.
MK3-02	List	Describe	Explain the signal Implement a		basic biostatistical testing and epidemiological
WIK5-02					principles.
MK3-03	Describe principles underlyi	ng research study design for	Generate a hypothesis and select methodology for	Perform data collection and analysis for; Disseminate findings of; Recognize components of grant writing and submission for	a scholarly project related to clinical practice, quality improvement, patient safety, medical education or research in collaboration with a faculty mentor.
MK3-04		Prepare and submit an abstrac	t	Prepare and submit a peer- reviewed manuscript; Prepare and submit a non- peer reviewed manuscript for publication (e.g. clinical review, book chapter)	to demonstrate effective scientific writing skills.
MK3-05		onferences, including but not d rounds, lay education, local al meetings	Present an abstract locally, regionally, or nationally		to disseminate scholarly work.
					principles of informed
MK3-06	List	Describe; Explain the significance of; Enact			principles of informed consent as it pertains to investigation, involving human subjects.

9. Works effectively within an interprofessional team (e.g., with peers, consultants, nursing, ancillary professionals, and other support personnel). (SBP1)

		Rheumatology	/ Curricular Milestones					
Number	By the listed time the fellow should be able to							
Number	6 months	12 months	18 months	24 months	For this curricular milestone			
SBP1-01	Acknowledge the contributions from	Actively participate and work with	]		health care providers from varied disciplines to promote patient-centered care.			
SBP1-02	Recognize the varied	Explain the contributions of	Participate in th	e activities of	health care providers who work to promote patient safety and to identify risks for and strategies to prevent medical errors.			
SBP1-03	List the individual components that contribute to	Ascribe levels of complexity to	the components that comprise	Implement	appropriate coding based on documentation and reimbursement policies.			
SBP1-04	Decsribes	Differentia	ates among	Works effectively within	the spectrum of practice models for health care delivery, including the fundamentals of office and personnel management.			

10. Recognizes	10. Recognizes system error and advocates for system improvement. (SBP2)										
Rheumatology Curricular Milestones											
Number		By the listed time the fe	ellow should be able to		For this curricular milestone						
Number	6 months	12 months	18 months	24 months	For this curricular milestone						
SBP2-01	Recognize situations leading to inefficiencies, safety concerns and/or preventable medical errors when	Participate in a system level quality improvement initiatives while	Design and implement a system level quality improvement initiative while		partnering with other healthcare teams and professionals to improve the quality of care and patient						
					safety within the system.						
SBP2-02	Demonstra	te ability to	Assist others within o Assist the	•	recognize opportunities to address causes of disparity in						
SDF2-U2					disease and healthcare delivery.						

11. Identifies forces that impact the cost of health care, and advocates for and practices cost-effective care. (SBP3)	
Rheumatology Curricular Milestones	

Number		By the listed time	By the listed time the fellow should be able to			
Number	6 months	12 months	18 months	24 months	For this curricular milestone	
SBP3-01	Recognize the necessity to integrate	Participate i	n decisions that reflect	Independently incorporate considerations of	cost awareness and cost benefit analysis for disease	
30F 3-01					specific care as well as in individual patients.	
	Recognize		/ ways to address; ate for change of	Implement measures to correct	barriers impacting patient care, including socio-	
SBP3-02					economic factors, healthcare literacy, medical disability and health care insurance coverage.	
	ldentify	Describe the impact c	on health care cost and access by	Leverage the advantages, for individual patients, of	the various health care settings (academic	
SBP3-03					/public/private/VA) and stakeholders in the healthcare economy.	

12. Transition	12. Transitions patients effectively within and across health delivery systems. (SBP4)										
Rheumatology Curricular Milestones											
Number	By the listed time the fellow should be able to										
Number	6 months	12 months	18 months	24 months	For this curricular milestone						
CDD4 01	Identify the providers, therapies, and potential obstacles to successfully	Discuss strategies to overcom	e the obstacles to successfully	Implement strategies to successfully	coordinate care across multiple delivery systems, including ambulatory,						
SBP4-01					subacute, acute, rehabilitation and skilled nursing facilities.						

3. Monitors practice with a goal for improvement. (PBLI1)								
		Rheumatolog	y Curricular Milestones					
Number	By the listed time the fellow should be able to							
Number	6 months	12 months	18 months	24 months	For this curricular mileston			
PBLI1-01	Acknowledge the importance of reflection to	Routinely reflect on clinical interactions to; Describe his or her own efforts to	Seek resources to address		identify(ied) knowledge or skills gaps to enhance future clinical interactions.			

		Recognize		Implement	ways to improve his/her role
PBLI1-02					in the effective management of a practice.

14. Learns and	improves via performa	nce audit. (PBLI2)			
		Rheumatology	Curricular Milestones		
Number		By the listed time the fe	ellow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular innestone
				Demonstrate through	learns from errors.
	Can describe what s/he	Independently identify	and describe what s/he	actions taken to improve	
PBLI2-01	Call describe what syne		and describe what sine	the system or processes of	
				care that s/he	
PBLI2-02		Identify an area of inquiry to dire	ct	Design the method for; Perform and analyze; Reflect on and hypothesize an explanation for deficiencies found (including doctor-related, system-related, and patient-related factors) through; Change practice based on results of	an audit of a panel of patients using standardized, disease-specific, and evidence-based criteria.

15. Learns and	improves via feedback. (	PBLI3)							
	Rheumatology Curricular Milestones								
Number		By the listed time the fell	ow should be able to		For this curricular milestone				
Number	6 months	12 months	18 months	24 months	For this curricular milestone				
PBLI3-01	Accept and r Actively seek an Develop plans for practice	nd reflect on;			feedback from all members of the health care team including faculty, peers, students, nurses, allied health workers, patients and their advocates.				

16. Learns and	improves at the point of	care. (PBLI4)			
		Rheumatology	Curricular Milestones		
Number		By the listed time the fe	ellow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular milestone
PBLI4-01	Identify basic knowledge gaps and seek	In all cases, independently construct and pursue	]		answers to clinical questions, and performs self-reflection to incorporate learning for future clinical encounters.
PBLI4-02	Independently	Teach others to			use(s) technology to manage information (HIPAA compliant), support patient care decisions using evidence-based medicine and enhance both patient and physician education.
PBLI4-03	With prompting from faculty	Independently	]		maintains awareness of the situation in the moment, and responds to meet situational needs.
PBLI4-04	Customizes manag Determines ar		]		clinical evidence for individualized patient care.

## 17. Has professional and respectful interactions with patients, caregivers, and members of the interprofessional team (e.g., peers, consultants, nursing, ancillary professionals, and support personnel). (PROF1)

		Rheumatology C	Curricular Milestones		
Number		By the listed time the felle	ow should be able to		For this curricular milestone
Number	6 months	12 months	18 months	24 months	For this curricular innestone
PROF1-01	Recognize and manage differe to Recognize and manage differ members of the interp Provide constructive feedba health care	; ences of opinion with other professional team to; ck to other members of the			demonstrate respectful professional interactions.
	Provide responsible team				demonstrate respect for
PROF1-02	leadership to				patient dignity and
					autonomy.

	Recognize, respond to, and report impairment in	as a demonstration of commitment to providing
PROF1-03	colleagues or substandard care via peer review process	safe patient care.

		Rheumatology	Curricular Milestones		
Number		By the listed time the fe	llow should be able to		For this curricular mileston
Number	6 months	12 months	18 months	24 months	
PROF2-01	Demonstrates appropriate professional appearance (1 month); Recognize the scope of his/her abilities and ask for supervision and assistance appropriately; When indicated, identify and assist colleagues in need of assistance in the provision of duties	Through his/her actions, serve as a professional role model for peers and learners	Contribute to the fiscally sound practice of an office		as demonstration of personal accountability.
PROF2-02	Respond promptly and appropriately to clinical responsibilities including but not limited to calls and pages; Carry out timely interactions with colleagues, patients, and their designated caregivers	Ensure prompt completion of clinical, administrative, curricular and research- related tasks			as a demonstration of the professional attribute of accessibility.

19. Responds	19. Responds to each patient's unique characteristics and needs. (PROF3)							
	Rheumatology Curricular Milestones							
Number	By the listed time the fellow should be able to				For this considerations			
Number	6 months	12 months	18 months	24 months	For this curricular milestone			
PROF3-01	Represent individual patient	Address disparities in health			as a demonstration of being			

	needs; Show empathy and compassion to all patients; Take responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases)	care among populations that may impact patient care	an advocate for all patients.
PROF3-02	Treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs; Make efforts to support (physical, psychological, social, and spiritual) patients with acute and chronic, basic and complex rheumatic diseases and their caregivers.		as a demonstration of showing compassion and respect to patients.

		Rheumatology	Curricular Milestones		
Number		By the listed time the fe	llow should be able to		For this curricular mileston
Number	6 months	12 months	18 months	24 months	For this curricular inneston
	Document and report clinical				as a demonstration of
	and research information				adhering to basic ethical
	truthfully;				principles.
	Follow formal policies;				
	Accept personal errors and				
PROF4-01	honestly acknowledge them;				
PROF4-01	Maintain patient				
	confidentiality;				
	Uphold ethical expectations				
	of clinical, scholarly activity				
	and research including				
	maintenance of up-to-date				

	certifications for all professional activities	
	Maintain and monitor	manage conflicts of interes
	patient care relationships	
	with colleagues, members of	
	the interprofessional team	
	and office staff to;	
	Use technology and social	
	media appropriately to;	
PROF4-02	Maintain ethical	
	relationships with industry	
	to;	
	Addresses personal,	
	psychological, and physical	
	limitations that may affect	
	professional performance to	

21. Communicates effectively with patients and caregivers. (ICS1)						
Rheumatology Curricular Milestones						
Number		For this surrigular milestone				
	6 months	12 months	18 months	24 months	For this curricular milestone	
ICS1-01	Use nonverbal skills, and without interruption; Ask thoughtful questions based on ability to				listen carefully to patients and caregivers to create rapport and build a therapeutic relationship.	
ICS1-02	Use plain language, avoiding technical medical terms, to; Appropriately use an interpreter to	Encourage questions, answering clearly, incorporating new insights to			explain and counsel patients and caregivers about their problems, proposed examinations and treatments, and findings.	
ICS1-03	Recognize the need to	Incorporate patient	Solicit and incorporate patient	Solicit and incorporate	share decision-making in	

	incorporate patient preferences to	preferences to	preferences surrounding uncomplicated situations to	patient preferences surrounding ambiguous or	both diagnostic and therapeutic scenarios.
				controversial situations to	
	Demonstrate sensitivity to	Actively seek to understand	Integrate into evaluation and management plans		differences in patients including, but not limited to
ICS1-04					race, culture, gender, sexual orientation, socioeconomic status, literacy, religious beliefs.

22. Communicates effectively in interprofessional teams (e.g., with peers, consultants, nursing, ancillary professionals, and other						
support personnel). (ICS2) Rheumatology Curricular Milestones						
	By the listed time the fellow should be able to					
Number	6 months	12 months	18 months	24 months	For this curricular milestone	
	Describe the importance of	Proactively initiate			communication with other	
ICS2-01					healthcare providers in order to maintain appropriate continuity during transitions of care, including from pediatric to adult rheumatology care.	
ICS2-02	Recognize the roles and acknowledge the contributions of individuals in support of	Interact, adapting and shifting roles as necessary, in support of	Initiate problem solving for; Assume a leadership role in the education of all members in support of		productive interaction within interprofessional teams.	
ICS2-03	Utilize common technologies for		tion technology, and verbal and al skills for	Role model proficiency in tailored topic selection, presentation technology, and verbal and nonverbal skills for	effective presentation for the specific audience.	

23. Appropriate utilization and completion of health records. (ICS3)				
Rheumatology Curricular Milestones				
Number	By the listed time the fellow should be able to	For this curricular milestone		

	6 months	12 months	18 months	24 months	
		Adjust communication on			timely and legible authentic
	Document through	the basis of context,	Organize complex cases into		documentation that includes
1052-01	templates/scripts to create	audience and/or situation for	relevant and succinct,		a differential diagnosis and
ICS3-01		relevant and succinct,			clinical reasoning, and
					support for the appropriate
					level of reimbursement.

## APPENDIX D. RHEUMATOLOGY TOOLBOX: ACTIVITIES AND ASSESSMENTS

### Rheumatology Toolbox for Tracking of Curricular Milestone Implementation

**Directions:** The Curricular Milestones are formatted in two different ways (Appendix C and below for the Rheumatology Toolbox). Utilizing the two far right columns in the Curricular Milestones tables, provided in the Rheumatology Toolbox, you may populate activities and assessment tools specific to your program that encompass each Curricular Milestone. You may utilize the provided list of activities and assessments and supplement with others that are unique to your program.

## **Activities**

Experience	Activity
Clinical experience in	General Rheumatology Continuity Clinic
mentored setting	
	Outpatient clinic
	o VA
	• Satellite office
	<ul> <li>Inflammatory arthritis</li> <li>Gout</li> </ul>
	o SLE
	o Scleroderma
	o Vasculitis
	<ul> <li>Myositis</li> </ul>
	<ul> <li>Pediatric Rheumatology</li> </ul>
	<ul> <li>Osteoporosis</li> </ul>
	<ul> <li>Rheumatology/Dermatology</li> </ul>
	<ul> <li>Rheumatology/Pulmonary</li> </ul>
	<ul> <li>Musculoskeletal ultrasound</li> </ul>
	o Other
	Inpatient consult service (by site)
	Inpatient Consult Service (by Site)
	Elective
	<ul> <li>Physical Medicine and Rehab</li> </ul>
	<ul> <li>Sports medicine</li> </ul>
	<ul> <li>Orthopaedics</li> </ul>
	<ul> <li>Pediatric orthopaedics</li> </ul>
	<ul> <li>PT/OT</li> <li>Podiatry</li> </ul>
	<ul> <li>Pain management</li> <li>Rheumatology private practice</li> </ul>
	• Other
Committee	Participation on committee
participation	<ul> <li>Division of Rheumatology</li> </ul>
	<ul> <li>Department of Medicine</li> </ul>
	o Regional
	o National
Didactics: Large group	Rheumatology Grand Rounds
Diadolioon Laigo group	Medicine Grand Rounds
	Rheumatology Core Curriculum Conference
	Evidence-Based Medicine Conference
	Rheumatology Journal Club
	Basic Science Journal Club
	Rheumatology Research Conference
	Basic Science Conference
	Immunology Conference
	Rheumatology/Radiology
	Rheumatology/Pathology
	Professors Rounds
	Rheumatology Case Conference
	Other Grand Rounds(     Other interview i
	Other interdisciplinary conference
	Summer Rheumatology Review
	Certificate/Degree program
	Attendance at
	Land Crasick, Cartananaa
	<ul> <li>Local Specialty Conferences</li> </ul>
	<ul> <li>Regional Specialty Conferences</li> </ul>
	<ul> <li>Regional Specialty Conferences</li> <li>National Conferences</li> </ul>
	<ul> <li>Regional Specialty Conferences</li> </ul>

	<ul> <li>ACR SOTA</li> </ul>			
Didactics: Small group	Faculty facilitated group discussion			
	Workshop participation			
Self study	Self Study Module			
	Independent Readings			
	o Textbook			
	<ul> <li>Journal articles</li> </ul>			
	<ul> <li>Internet based research</li> </ul>			
	<ul> <li>Internet based study</li> </ul>			
	<ul> <li>Web-based modules</li> </ul>			
	o Other			
Fellow projects and	Presentation by Fellow			
presentations	<ul> <li>Rheumatology journal club</li> </ul>			
	<ul> <li>Basic science journal club</li> </ul>			
	• Research conference			
	• Case conference			
	<ul> <li>Rheumatology Grand Rounds</li> </ul>			
	<ul> <li>Community education</li> </ul>			
	o Other			
	Preparation of patient care portfolio			
	Clinical research project			
	Basic science research project			
	• QI			
	Patient safety project			
	Scientific writing			
	Abstract presentation			
	o Poster			
	o Podium			
Simulation	Simulation with models			
	Simulation with standardized patients			

## Assessment Tools

Methods	Rheumatology Assessment Tools
Anatomic model	Joint simulator
	Cadaver lab
Direct Observation	Mini CEX (clinical)
	Mini-PEX (procedure)
ACR In training exam	
Multisource	Self- assessment
assessment	Faculty evaluations (rotations)
	Faculty evaluations (3, 6 mo)
	Research mentor evaluation
	360 degree (administrative, nursing, health professionals, technical staff)
	• Peer
	Patient evaluations
	<ul> <li>Procedural Competency Assessment (arthrocentesis evaluation form, 6</li> </ul>
	months)
	Semiannual Program Director review
	<ul> <li>ACGME Reporting Milestones by Clinical Competency Committee</li> </ul>
Objective structured	
clinical exam (OSCE)	
Videotaped or	
recorded assessment	
Oral Examination	
Practice/billing audit	Medical documentation review
Presentation skills	Feedback forms for presentations
	Rheumatology Journal Club
	Basic Science Journal Club
	Grand Rounds
	Case Conference
	Morbidity and Mortality
Project assessment	• QI

by faculty	Research
Record/chart review	
Trainee experience narrative	Reflection
Review case/procedure log	
Review of drug prescribing	
Review of patient	QI project
outcomes	Registry review
Role play or simulations	
Simulations/models	Joint injection
Standardized patient	
exams	
Structured case	
discussions	
	Portfolio review

# Rheumatology Curricular Milestones Tables

## MEDICAL KNOWLEDGE

			Rheumato	logy Curricular Milestones	Your Train	ing Program
Subspecialty Reporting Milestone	Number	By this time (months)	The fellow should be able to	For this curricular milestone	Activities	Assessment Tools
Clinical Knowledge		12	Demonstrate basic	knowledge of the relevant structure and function of the musculoskeletal system,		
(MK1)	MK1-01	24	Demonstrate comprehensive	immune system and basic science for describing the pathophysiology of rheumatologic conditions.		
		6	Acknowledge the indications for			
	MK1-02	12	Independently distinguish indications for	referrals to other subspecialists and ancillary services including orthopedics and rehabilitation medicine.		
	WIK1-UZ	18	Independently formulate specific consultative questions for			
		6	List			
	MK1-03	12	Explain	relevant mechanisms of action and potential adverse effects of agents used in the management of patients with rheumatologic conditions.		
-		18	Differentiate subtle differences in			
	MK1-04	12	Report on	the anatomy, physiology and management of pain in patients with rheumatologic conditions.		
		18	Teach others			
		12	List	<ul> <li>similarities and differences of the clinical presentation and management between adults and children with rheumatic conditions.</li> </ul>		
	MK1-05	18	Describe in detail			
		24	Explain the significance of			
		6	In uncomplicated cases, construct			
		12	In cases demonstrating increasing complexity, construct	a differential diagnosis for rheumatologic conditions, including consideration of non-rheumatic diseases.		
	MK1-06	18	In highly complex cases, with multi- system involvement, construct			
		24	Teach others to construct			
	MK1-07	12	Demonstrate basic	knowledge regarding the need for preventive care in patients with rheumatic conditions.		
	WIKT-07	18	Demonstrate comprehensive	Conditions.		
	MK1-08	12	Demonstrate basic	knowledge to evaluate complex rheumatic diseases in the setting of multiple		

			Demonstrate comprehensive	coexistent conditions, including the effects of aging.	
		18			
	MK1-09	12	Demonstrate basic	knowledge of socio-behavioral sciences including but not limited to health care economics and medical ethics.	
		24	Demonstrate comprehensive		
Knowledge of Diagnostic Testing and		6	Identify		
Procedures (MK2)		12	Describe	indications, risks and benefits of rheumatologic diagnostic testing, including but	
	MK2-01	18	Differentiate	not limited to immunoassays, synovial fluid analysis, routine blood chemistries, hematologic studies, coagulation studies, radiographs, and DXA scanning.	
		24	Teach		
	N#2 02	12	Explain	major findings and interpretation of rheumatologic diagnostic testing, including but not limited to immunoassays, synovial fluid analysis, routine blood	
	MK2-02	24	Teach others about	chemistries, hematologic studies, coagulation studies, radiographs, and DXA scanning.	
		6	List	indications, risks and benefits for more advanced diagnostic tests including	
	MK2-03	18	Explain	imaging techniques (isotopic, PET, CT and MRI scanning, angiography and musculoskeletal ultrasound) and pathologic examination of tissues involved with	
		24	Differentiate	rheumatic diseases.	
	14//2 04	12	Explain	major findings and interpretation of more advanced diagnostic tests including imaging techniques (isotopic, PET, CT and MRI scanning, angiography and	
	MK2-04	24	Teach others about	musculoskeletal ultrasound) and pathologic examination of tissues involved with rheumatic diseases.	
Scholarship (MK3)	MK3-01	6	Demonstrate basic	knowledge of principles underlying critical appraisal of the medical literature.	
		24	Demonstrate comprehensive		
		6	List		
	MK2 02	12	Describe	basic biostatistical testing and epidemiological principles.	
	MK3-02	24	Explain the significance of		
		24	Implement and interpret		
		12	Describe principles underlying research study design for		
	MK2 02	18	Generate a hypothesis and select methodology for	a scholarly project related to clinical practice, quality improvement, patient	
	MK3-03	24	Perform data collection and analysis for	safety, medical education or research in collaboration with a faculty mentor.	
		24	Disseminate findings of		
		24	Recognize components of grant writing and submission for		
		18	Prepare and submit an abstract		
				to demonstrate effective scientific writing skills.	
	MK3-05	24	Prepare and submit a peer-reviewed manuscript		

		24	Prepare and submit a non-peer reviewed manuscript for publication (e.g. clinical review, book chapter)		
	MK3-06	12	Effectively present orally at conferences, including but not limited to rheumatology grand rounds, lay education, local and national meetings	to disseminate scholarly work.	
		18	Present an abstract locally, regionally, or nationally		
		6	List	principles of informed consent as it pertains to investigation, involving human	
	MK3-07	12			
		12	Explain the significance of		
		12	Enact		

### PATIENT CARE

			Rheumato	Your Traini	ng Program	
Subspecialty Reporting Milestone	Number	By this time (months)	The fellow should be able to	For this curricular milestone	Activities	Assessment Tools
Gathers and synthesizes		6	Obtain and report			
essential and accurate information to define each patient's clinical problem(s). (PC1)	PC1-01	12	Formulate with relevance	a comprehensive, accurate history, including review of all available records,		
	FCI-01	18	Incorporate	on patients with rheumatic symptoms and signs.		
	Ī	18	Teach others the elements of			
		12	Perform and report			
		18	Distinguish with relevance	a comprehensive, accurate physical examination, using common and advanced		
	PC1-02	18	Integrate	techniques where applicable, on patients with rheumatic symptoms and signs.		
	l t	24	Teach others to perform			
		6	Order and review			
P	Ī	12	Interpret	diagnostic tests including, but not limited to, laboratory, imaging, electrodiagnostic and pathologic studies for the evaluation of the patient with rheumatic symptoms and signs.		
	PC1-03	18	Incorporate			
		24	Teach others about the clinical application of			
		6	List the steps of			
	PC1-04	12	Recognize normal anatomy	using a standardized approach to the interpretation of musculoskeletal plain		
	101-04	18	Differentiate abnormal findings	radiographs.		
		24	Teach others to detect abnormalities			
	PC1-05	12	Describe applications, indications and limitations	using a standardized approach for the interpretation of musculoskeletal		
	PC1-05	24	Recognize normal anatomy	ultrasonography for diagnostic purposes.		
		24	Differentiate abnormal findings			
	PC1-06	6	Recognize the need to	collaboratively review imaging and tissue specimens with radiology and		
	PC1-06	12	Without faculty member prompting,	pathology services, respectively, to enhance patient safety and care		
Develops and achieves		6	List the components of			
omprehensive nanagement plan for	DC2 01	12	For uncomplicated presentations construct and implement	a comprehensive treatment plan, based on clinical evidence, clinical		
ach patient. (PC2)	PC2-01	18	For complicated presentations construct and implement	context, and patient preferences, counsel patients, and assess response to therapy.		
	†	24	Teach others to formulate			

			1		
			Describe state and federal regulations for		
		6	prescription of controlled substances as part		
			of		
		12	Describe non-pharmacologic and		
	PC2-02		pharmacologic components of	a pain management strategy of the care plan.	
			Implement, and monitor response to		
			therapy, patient compliance, and detect		
		12	signs and symptoms indicative of analgesic		
			abuse as part of		
			Describes indications and potential adverse		
		6	events of		
		10	Obtains verbal or written informed consent		
	PC2-03	12	for treatment with	pharmacotherapy, including immunomodulatory agents, used in the	
		18	Prescribe, monitor and assess response to	management of patients with rheumatic diseases.	
		24	Teaches others to prescribe, monitor and		
		24	assess response to		
			In comparison to adults, discuss the		
		12	similarities and differences in drug	pharmacotherapies for use in children and adelessents with the matter	
	PC2-04		disposition and its consequences regarding	pharmacotherapies for use in children and adolescents with rheumatic diseases.	
		12	List the currently used	uiseases.	
		24	Prescribe and adjust accordingly		
		12	Discuss how the changes in		
		12	pharmacokinetics that occur with age affect	therapeutic and management strategies in the aging population with rheumatic	
	PC2-05	18	Prescribe and adjust appropriately	diseases.	
		24	Teach others about		
		6	List options for	exercise and other rehabilitation strategies in the care of patients with rheumatic disorders.	
	PC2-06	12	Describe applications and indications for		
	PC2-06	18	Incorporate		
		24	Teach others to incorporate		
		6	With attending supervision		
	PC2-07	12	With attending supervision for complicated presentations	formulate and implement a management plan for patients with rheumatic emergencies (including organ or life threatening conditions), with a need for emergent, urgent or changes in level or goals of care.	
	1 62 07	24	Independently		
		24	Teach others to		
Manages patients with		6	Describe the potential manifestations of		
progressive		12	Formulate plans to screen for and manage	disease-related exacerbations and the influence of comorbid illness during the	
responsibility and	PC3-01	18	Implement and monitor plans for	provision of longitudinal and customized care to patients with rheumatic	
independence. (PC3)		24	Teach others to recognize and manage	diseases.	
		6	Identify		
		12	Formulate plans to screen, assess severity,	disease and treatment related complications that may load to loss terms	
	PC3-02	12	and manage	disease- and treatment-related complications that may lead to long term morbidity, including the consideration for implications of comorbid diseases and	
	F C3-02	18	Implement and monitor plans to screen,	the effects of aging.	
			assess severity, and manage	the effects of aging.	
		24	Teach others to recognize and manage		
		6	Recognize		
	PC3-03	18	Develop strategies to manage	the psychosocial aspects of rheumatic diseases.	
		24	Implement strategies to manage		
	DC2 01	6	List and describe the utility of	the varied validated instruments in the assessment of pain, disease activity,	
	PC3-04	12	Incorporate into practice	function, and quality of life over time to monitor and adjust therapy.	
Chill in nonforming		18	Teach others to incorporate into practice		
Skill in performing procedures. (PC4)	DC4 04	6	With attending supervision	obtain verbal or written informed consent from patient or caregiver for	
procedures. (PC4)	PC4-01	12 12	Independently	procedures.	
	<u> </u>		Teach others to		
	PC4-02	6	With attending supervision	perform procedures including arthrocentesis and joint and soft tissue injections.	
	1	18	With attending assistance for those that are		

[	1			
			complicated or previously unperformed	
		24	Independently	
		24	Teach others to	
		24	With attending supervision	
		24	With attending assistance for those that are	
	PC4-03	24	complicated or previously unperformed	perform procedures including arthrocentesis and joint and soft tissue injections
		24	Independently	with ultrasound guidance, when appropriate and feasible.
		24	Teach others to	
		6	With attending supervision	
	PC4-04	12	Independently	perform compensated polarized microscopy to examine and interpret synovial fluid.
		18	Teach others to	nua.
Requests and provides		6	Identify the indications to	
consultative care. (PC5)	PC5-01	12	Proactively	refer to other healthcare providers for the co-management of patients with
		18	Teach others why, when, and how to	rheumatic disease.
		6	Recognize the tissues commonly considered for	
	PC5-02	12	List the indications, expected risks and benefits, and available alternatives for	diagnostic biopsies (including, but not limited to, temporal artery, renal, lung, muscle, nerve, skin, minor salivary gland, and brain) in the evaluation
		18	Implement plans to refer for	of rheumatic diseases, and refers when indicated and appropriate.
		18	Teach others how to incorporate	
		18	Identify opportunities for referral	
	PC5-03	24	Refer when indicated	to clinical registries and trials.
		6	With attending supervision	provide consultation when requested, in support of the primary care relationship, for patients with rheumatic symptoms and signs and
	PC5-04	24	Independently	appropriately integrate recommendations from other healthcare providers into the evaluation and management plan.

PRACTICE-

### BASED LEARNING AND IMPROVEMENT

	Rheumatology Curricular Milestones Your Training I					Program
Subspecialty Reporting Milestone	Number	Activities	Activities	For this curricular milestone Act	tivities	Assessment Tools
Monitors Practice		6	Acknowledge the importance of reflection to			
vith goal for mprovement (PBLI1)		12	Routinely reflect on clinical interactions to			
improvement (PBLII)	PBLI1-01	12	Describe his or her own efforts to	identify(ied) knowledge or skills gaps to enhance future clinical interactions.		
		18	Seek resources to address			
	PBLI1-02	18	Recognize			
		24	Implement	ways to improve his/her role in the effective management of a practice.		
Learns and improves		6	Can describe what s/he			
via performance audit. (PBLI2)	PBLI2-	18	Independently identify and describe what s/he	learns from errors.		
	01	24	Demonstrate through actions taken to improve the system or processes of care that s/he			
	PBLI2-	18	Identify an area of inquiry to direct	an audit of a panel of nationte using standardized, disease specific, and		
	02	24	Design the method for	an audit of a panel of patients using standardized, disease-specific, and evidence-based criteria.		
	52	24	Perform and analyze	evidence-based citteria.		

		24	Reflect on and hypothesize an explanation for deficiencies found (including doctor- related, system-related, and patient- related factors) through Change practice based on results of		
Learns and improves via feedback. (PBLI3)		12	Accept and reflect on		
	PBLI3- 01	12	Actively seek and reflect on	feedback from all members of the health care team including faculty, peers, students, nurses, allied health workers, patients and their advocates.	
		12	Develop plans for practice improvement based on		
Learns and improves	PBLI4-	6	Identify basic knowledge gaps and seek	answer to elinical questions, and parforms self-reflection to incorporate	
at the point of care. (PBLI4)	01	12	In all cases, independently construct and pursue	answers to clinical questions, and performs self-reflection to incorporate learning for future clinical encounters.	
()	PBLI4-	6	Independently	use(s) technology to manage information (HIPAA compliant), support patient	
	02	12	Teach others to	care decisions using evidence-based medicine and enhance both patient and physician education.	
	PBLI4-	6	With prompting from faculty	maintains awareness of the situation in the moment, and responds to meet	
	03	12	Independently	situational needs.	
	PBLI4-	12	Determines applicability of	clinical evidence for individualized patient care.	
	04	12	Customizes management based on		

#### SYSTEMS BASED PRACTICE

			Rheumato	Your Training Program		
Subspecialty Reporting Milestone	Number	By this time (months)	The fellow should be able to	For this curricular milestone	Activities	Assessment Tools
Works effectively	SBP1-01	6	Acknowledge the contributions from	health care providers from varied disciplines to promote patient contered care		
within an interprofessional team	2861-01	12	Actively participate and work with	health care providers from varied disciplines to promote patient-centered care.		
(e.g. peers,		6	Recognize the varied	health care providers who work to promote patient safety and to identify risks		
consultants, nursing,	SBP1-02	12	Explain the contributions of	for and strategies to prevent medical errors.		
therapists, nurses,		24	Participate in the activities of			
home care workers, pharmacists, social	SBP1-03	6	List the individual components that contribute to	appropriate coding based on documentation and reimbursement policies.		
workers and other ancillary professionals and other support		18	Ascribe levels of complexity to the components that comprise			
personnel). (SBP1)		24	Implement			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	SBP1-04	6	Describes	the spectrum of practice models for health care delivery, including the fundamentals of office and personnel management.		
		18	Differentiates among			
		24	Works effectively within			
Recognizes system error and advocates for system improvement.	SBP2-01	Recognize situations leading to 6 inefficiencies, safety concerns and/or preventable medical errors when				
(SPB2)		12	Participate in a system level quality improvement initiatives while	partnering with other healthcare teams and professionals to improve the quality of care and patient safety within the system.		
		24	Design and implement a system level			
		12	quality improvement initiative while Demonstrate ability to			
	SBP2-02	24	Assist others within one's own system to	recognize opportunities to address causes of disparity in disease and healthcare		
		24	Assist others within one's own system to	delivery.		

		24	Assist the public to		
Identifies factors that		6	Recognize the necessity to integrate	cost awareness and cost benefit analysis for disease specific care as well as in individual patients.	
impact the cost of	SBP3-01	18	Participate in decisions that reflect		
health care, and advocates for, and	2863-01 -	24	Independently incorporate considerations of		
practices cost-effective		6	Recognize		
care. (SBP3)	SBP3-02	18	Identify ways to address	barriers impacting patient care, including socio-economic factors, healthcare	
	3DP3-02	18	Advocate for change of	literacy, medical disability and health care insurance coverage.	
		24	Implement measures to correct		
		6	Identify	the various health care settings (academic/public/private/VA) and stakeholders in the healthcare economy.	
	SBP3-03	18	Describe the impact on health care cost and access by		
		24	Leverage the advantages, for individual patients, of		
Transitions patients effectively within and across health delivery systems. (SBP4)		6	Identify the providers, therapies, and potential obstacles to successfully	coordinate care across multiple delivery systems, including ambulatory, subacute, acute, rehabilitation and skilled nursing facilities.	
	SBP4-01	18	Discuss strategies to overcome the obstacles to successfully		
		24	Implement strategies to successfully		

## INTERPERSONAL AND COMMUNICATION SKILLS

			Rheumatol	Your Training Program		
Subspecialty Reporting Milestone	Number	By this time (months)	The fellow should be able to	For this curricular milestone	Activities	Assessment Tools
Communicates effectively with patients	ICS1-01	6	Use nonverbal skills, and without interruption	listen carefully to patients and caregivers to create rapport and build a therapeutic relationship.		
and caregivers. (ICS1)		6	Ask thoughtful questions based on ability to			
		6	Use plain language, avoiding technical medical terms, to			
	ICS1-02	6	Appropriately use an interpreter to	explain and counsel patients and caregivers about their problems, proposed examinations and treatments, and findings.		
		12	Encourage questions, answering clearly, incorporating new insights to	examinations and treatments, and minings.		
	ICS1-03	6	Recognize the need to incorporate patient preferences to	share decision-making in both diagnostic and therapeutic scenarios.		
		12	Incorporate patient preferences to			
		18	Solicit and incorporate patient preferences surrounding uncomplicated situations to			
		24	Solicit and incorporate patient preferences surrounding ambiguous or controversial situations to			
		6	Demonstrate sensitivity to			
	ICS1-04	12	Actively seek to understand	differences in patients including, but not limited to race, culture, gender, sexual		
		18	Integrate into evaluation and management plans	orientation, socioeconomic status, literacy, religious beliefs.		
Communicates effectively in	ICS2-01	6	Describe the importance of	communication with other healthcare providers in order to maintain appropriate continuity during transitions of care, including from pediatric to		
interprofessional teams		12	Proactively initiate	adult rheumatology care.		

(e.g., with peers, consultants, nursing, ancillary professionals, and other support personnel). (ICS2)	ICS2-02	6 12 18 18	Recognize the roles and acknowledge the contributions of individuals in support of Interact, adapting and shifting roles as necessary, in support of Initiate problem solving for Assume a leadership role in the education of all members in support of	productive interaction within interprofessional teams.
		6	Utilize common technologies for	
	ICS2-03	18	Tailor topic selection, presentation technology, and verbal and nonverbal skills for	effective presentation for the specific audience.
		24	Role model proficiency in tailored topic selection, presentation technology, and verbal and nonverbal skills for	
Appropriate utilization and completion of		6	Document through templates/scripts to create	
health records. (ICS3)	ICS3-01	12	Adjust communication on the basis of context, audience and/or situation for relevant and succinct,	timely and legible authentic documentation that includes a differential diagnosis and clinical reasoning, and support for the appropriate level of reimbursement.
		18	Organize complex cases into relevant and succinct,	

### PROFESSIONALISM

			Rheumatol	Your Training Program		
Subspecialty Reporting Milestone	Number	Activities	Activities	For this curricular milestone	Activities	Assessment Tools
Has professional and respectful interactions with patients, caregivers, and	PROF1- 01	12	Recognize and manage differences of opinion with patients to Recognize and manage differences of opinion with other members of the	demonstrate respectful professional interactions.		
members of the interprofessional team (e.g., peers, consultants, nursing, ancillary	PROF1-	12	interprofessional team to Provide constructive feedback to other members of the health care team to			
professionals, and support personnel). (PROF1)	02 PROF1- 03	6	Provide responsible team leadership to Recognize, respond to, and report impairment in colleagues or substandard care via peer review process	demonstrate respect for patient dignity and autonomy. as a demonstration of commitment to providing safe patient care.		
Accepts responsibility and follows through on tasks. (PROF2)	PROF2- 01	6	Recognize the scope of his/her abilities and ask for supervision and assistance appropriately When indicated, identify and assist	as demonstration of personal accountability.		
		6	colleagues in need of assistance in the provision of duties			
		12	Through his/her actions, serve as a professional role model for peers and learners Contribute to the fiscally sound practice of			
		24	an office			

ſ	1	1		
		1	Demonstrates appropriate professional appearance	
		6	Respond promptly and appropriately to clinical responsibilities including but not limited to calls and pages	
	PROF2- 02	6	Carry out timely interactions with colleagues, patients, and their designated caregivers	as a demonstration of the professional attribute of accessibility.
		12	Ensure prompt completion of clinical, administrative, curricular and research- related tasks	
Responds to each		6	Represent individual patient needs	
patient's unique characteristics and	PROF3-		Show empathy and compassion to all patients	
needs. (PROF3)	01	12	Address disparities in health care among populations that may impact patient care	as a demonstration of being an advocate for all patients.
		6	Take responsibility for situations where public health supersedes individual privacy (e.g. reportable infectious diseases)	
	PROF3-	6	Treat patients with dignity, civility and respect, regardless of race, culture, gender, sexual orientation, socioeconomic status, literacy, and religious beliefs	as a demonstration of showing compassion and respect to patients.
	02	6	Make efforts to support (physical,	as a demonstration of showing compassion and respect to patients.
Exhibits integrity and ethical behavior in	PROF4-	6	Document and report clinical and research information truthfully	
professional conduct.		6	Follow formal policies	
(PROF4)		6	Accept personal errors and honestly acknowledge them	
	01	6	Maintain patient confidentiality	as a demonstration of adhering to basic ethical principles.
		6	Uphold ethical expectations of clinical, scholarly activity and research including maintenance of up-to-date certifications for all professional activities	
		6	Maintain and monitor patient care relationships with colleagues, members of the interprofessional team and office staff to	
	PROF4- 02	6	appropriately to manage conflicts of interest.	manage conflicts of interest.
		6	Maintain ethical relationships with industry to	
		6	Addresses personal, psychological, and physical limitations that may affect professional performance to	

# AMERICAN COLLEGE OF RHEUMATOLOGY

Curriculum Subcommittee Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues Roster 2019-2020

# <u>Chair</u>

Lisa Criscione-Schreiber, MD, MEd (2014-2021) Duke University School of Medicine Box 3490 DUMC Durham, NC, 27710 Email: <u>lisa.criscione@duke.edu</u>

# Narender Annapureddy, MD (2018-2021)

Vanderbilt University – Rheumatology 1161 21st Avenue S Nashville, TN. 37203 Email: <u>narender.annapureddy@vanderbilt.edu</u>

# Adam Berlinberg, MD (2019-2022)

Fellow-in-Training University of Colorado 550 E. 12th Ave Denver, CO 80203, US Email: adam.berlinberg@ucdenver.edu

# Christopher Collins, MD (2018-2020)

Georgetown University Hospital/Washington Hospital Center 110 Irving St. NW. Rm 2A-52 Washington, DC. 20010 Email: <u>chriscollinsmd@hotmail.com</u>

# Chase Correia, MD (2017-2020)

Northwestern University 3556 South Seeley Avenue Unit 301 Chicago, IL 60609 E-mail: <u>Chase.Correia@northwestern.edu</u>

# Sam Dalvi, MD (2017-2020)

University of Alabama at Birmingham Faculty Office Tower, Room 844 1960 6th Ave South Birmingham, AL 35233 Email: sdalvi@uabmc.edu

# Sharon Dowell, MD (2018-2021)

Howard University College of Medicine 2041 Georgia Ave NW, Washington, DC 20060 Email: sharon.dowell@Howard.edu

# Evelyn Hsieh, MD, MPH (2014-2020)

Yale University School of Medicine 300 Cedar St. TAC 5525 New Haven, CT. 06520 Email: <u>evelyn.hsieh@yale.edu</u>

# Kabita Nanda, MD (2017-2020)

Pediatrics Seattle Children's Hospital 4800 Sand Point Way NE, MA.7.110 Seattle, WA 98105 Email: <u>kabita.nanda@seattlechildrens.org</u>

# Rochella Ostrowski, MD, MS (2019-2022)

Loyola University 2160 S 1st Ave Maywood, IL 60153 Email: <u>rostrowski@lumc.edu</u>

# Lisa Zickuhr, MD (2019-2022)

Washington University/B-JH/SLCH Consortium CB 8045, 660 S Euclid Ave St. Louis, MO 63110 Email: <u>zickuhrl@wustl.edu</u>

# ACKNOWLEDGEMENTS

The authors acknowledge and thank the following contributors to the current and past versions of the Core Curriculum Outline:

The Core Curriculum Outline 2006 Training Guidelines & Assessment Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues for developing the 2006 ACR Core Curriculum, on which the 2015 and 2020 versions of the Core Curriculum Outline are based. Members of the 2006 Training Guidelines & Assessment Subcommittee include David Daikh, MD, PhD (Chair), Richard D. Brasington, Jr., MD, Andre Barkhuizen, MD, Winn Chatham, MD, Howard Fuchs, MD, Gloria Higgins, PhD, MD, Neal Roberts, MD, Arthur Weinstein, MD, Ernesto Zatarain, MD, and Deirdre Lynch, PhD (ACGME Invited Guest).

The Next Accreditation System Working Group of the ACR Committee of Rheumatology Training and Workforce Issues for developing the 2015 Core Curriculum Outline, on which the 2020 version of the Core Curriculum Outline is based. Members of the Next Accreditation System Working Group included Marcy B. Bolster, MD (Co-Chair), Calvin R. Brown Jr, MD (Co-Chair), Lisa Criscione-Schreiber, MD, MEd, Howard Fuchs, MD, Evelyn Hsieh, MD, PhD, Kenneth S. O'Rourke, MD, Chaim Putterman, MD, Irene J. Tan, MD, and Joanne Valeriano-Marcet, MD.

Past members of Curriculum Subcommittee of the ACR Committee on Rheumatology Training and Workforce Issues who contributed to this revision: Joanne Valeriano-Marcet, MD (Chair 2017-2019), Irene J. Tan, MD, Zachary S. Wallace, MD, Marcy B. Bolster, MD, and Chaim Putterman, MD.

Pediatrics Core Curriculum Outline Stacey Tarvin, FACR,MD,MS, Jennifer Huggins, MD, Tracey Wright, MD, Ashley Cooper, MD, Katherine Marzan, MD, Alisa Gotte, MD, MSc